HTG Molecular Diagnostics (HTGMQ) 10-Q 10 Nov 21 2021 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2021	Nov. 05, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q3
Trading Symbol	HTGM
Entity Registrant Name	HTG Molecular Diagnostics, Inc
Entity Central Index Key	0001169987
Entity Current Reporting Status	Yes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Shell Company	false
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		7,567,759
Entity File Number	001-37369
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	86-0912294
Entity Address, Address Line One	3430 E. Global Loop
Entity Address, City or Town	Tucson
Entity Address, State or Province	AZ
Entity Address, Postal Zip Code	85706
City Area Code	(877)
Local Phone Number	289-2615
Document Quarterly Report	true
Document Transition Report	false
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common Stock, $0.001 par value per share
Security Exchange Name	NASDAQ

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 10,229,646	$ 22,397,812
Short-term investments available-for-sale, at fair value	15,187,672	6,298,075
Accounts receivable	1,904,534	1,588,767
Inventory, net of allowance of $16,393 at September 30, 2021 and $26,052 at December 31, 2020	2,340,766	1,492,126
Prepaid expenses and other	2,082,410	1,094,273
Total current assets	31,745,028	32,871,053
Operating lease right-of-use assets	1,444,348	1,009,097
Property and equipment, net	1,219,190	1,227,402
Other non-current assets	98,828	90,356
Total assets	34,507,394	35,197,908
Current liabilities:
Accounts payable	1,145,868	1,348,762
Accrued liabilities	1,609,001	1,459,878
Contract liabilities – current	213,462	185,083
NuvoGen obligation – current	530,657	512,729
Current portion of long-term debt	4,167,107	3,022,139
Operating lease liabilities – current	398,313	685,220
Other current liabilities	17,558	22,563
Total current liabilities	8,081,966	7,236,374
NuvoGen obligation - non-current, net of discount	4,072,831	4,479,396
Long-term debt, net of current portion, discount and debt issuance costs	6,309,416	8,568,308
Operating lease liabilities - non-current	1,055,984	368,682
Other non-current liabilities	99,825	60,488
Total liabilities	19,620,022	20,713,248
Commitments and Contingencies (Note 15)
Stockholders’ equity:
Series A convertible preferred stock, $0.001 par value; 23,770 shares authorized, issued and outstanding at September 30, 2021 and December 31, 2020	24	24
Common stock, $0.001 par value; 26,666,667 shares authorized at September 30, 2021 and December 31, 2020, 7,513,733 shares issued and outstanding at September 30, 2021 and 5,199,997 shares issued and outstanding at December 31, 2020	7,514	5,200
Additional paid-in-capital	218,018,993	205,661,999
Accumulated other comprehensive income	2,583	5,298
Accumulated deficit	(203,141,742)	(191,187,861)
Total stockholders’ equity	14,887,372	14,484,660
Total liabilities and stockholders' equity	$ 34,507,394	$ 35,197,908

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Inventory net allowance	$ 16,393	$ 26,052
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	26,666,667	26,666,667
Common stock, shares issued	7,513,733	5,199,997
Common stock, shares outstanding	7,513,733	5,199,997
Series A Convertible Preferred Stock
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	23,770	23,770
Preferred stock, shares issued	23,770	23,770
Preferred stock, shares outstanding	23,770	23,770

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Revenue:
Total revenue	$ 2,520,410	$ 1,777,098	$ 6,029,760	$ 5,965,866
Operating expenses:
Cost of product and product-related services revenue	$ 983,761	$ 940,892	$ 2,740,004	$ 2,931,026
Cost, Product and Service [Extensible Enumeration]	Product revenue, us-gaap:ServiceMember	Product revenue, us-gaap:ServiceMember	Product revenue, us-gaap:ServiceMember	Product revenue, us-gaap:ServiceMember
Selling, general and administrative	$ 4,232,313	$ 4,752,321	$ 11,995,747	$ 13,683,069
Research and development	1,534,818	1,255,416	4,188,219	4,914,467
Total operating expenses	6,750,892	6,948,629	18,923,970	21,528,562
Operating loss	(4,230,482)	(5,171,531)	(12,894,210)	(15,562,696)
Other income (expense):
Interest expense	(266,593)	(273,312)	(797,239)	(749,401)
Interest income	8,387	34,636	22,419	244,534
Other income				22,268
Gain on forgiveness of PPP Loan			1,735,792
Loss on extinguishment of MidCap Credit Facility and QNAH Convertible Note				(522,394)
Total other income (expense)	(258,206)	(238,676)	960,972	(1,004,993)
Net loss before income taxes	(4,488,688)	(5,410,207)	(11,933,238)	(16,567,689)
Provision for income taxes	(1,934)	(1,581)	(20,643)	(12,548)
Net loss	$ (4,490,622)	$ (5,411,788)	$ (11,953,881)	$ (16,580,237)
Net loss per share, basic and diluted	$ (0.60)	$ (1.12)	$ (1.78)	$ (3.68)
Shares used in computing net loss per share, basic and diluted	7,440,287	4,821,562	6,727,916	4,504,469
Product and Product-related Services
Revenue:
Total revenue	$ 2,520,410	$ 1,701,068	$ 6,029,760	$ 5,417,731
Collaborative Development Services
Revenue:
Total revenue		$ 76,030		$ 548,135

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Loss - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Statement Of Income And Comprehensive Income [Abstract]
Net loss	$ (4,490,622)	$ (5,411,788)	$ (11,953,881)	$ (16,580,237)
Other comprehensive income (loss), net of tax effect:
Unrealized gain (loss) on short-term investments	0	(17,501)	0	4,060
Foreign currency translation adjustment	(1,013)	1,225	(2,715)	7,631
Total other comprehensive income (loss)	(1,013)	(16,276)	(2,715)	11,691
Comprehensive loss	$ (4,491,635)	$ (5,428,064)	$ (11,956,596)	$ (16,568,546)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Stockholders' Equity - USD ($)	Total	LP Purchase Agreement	ATM Offering	Private Placement	Series A Convertible Preferred Stock	Series A Convertible Preferred StockPrivate Placement	Common Stock	Common StockLP Purchase Agreement	Common StockATM Offering	Additional Paid-In Capital	Additional Paid-In CapitalLP Purchase Agreement	Additional Paid-In CapitalATM Offering	Additional Paid-In CapitalPrivate Placement	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Balance at Dec. 31, 2019	$ 23,969,634						$ 3,873			$ 194,288,368				$ (4,964)	$ (170,317,643)
Balance, shares at Dec. 31, 2019							3,872,682
Stock-based compensation expense	415,256									415,256
Release of restricted stock awards	36						$ 2			34
Release of restricted stock awards, shares							2,396
Net share settlement of restricted stock awards	(7,052)						$ (1)			(7,051)
Net share settlement of restricted stock award, shares							(751)
Employee stock purchase plan expense	5,379									5,379
Issuance of common stock			$ 2,435,912					$ 41	$ 293		$ (41)	$ 2,435,619
Issuance of common stock, shares								41,026	293,271
Issuance of preferred stock	2,424,900			$ 562,955	$ 41	$ 10				2,424,859			$ 562,945
Issuance of preferred stock, shares					41,100	10,170
Cancellation of common stock received in exchange for Series A convertible preferred stock	(2,424,900)						$ (274)			(2,424,626)
Cancellation of common stock received in exchange for Series A convertible preferred stock, shares							(274,000)
Exercise of pre-funded warrants	31,768						$ 212			31,556
Exercise of pre-funded warrants, shares							211,784
Adjustment in connection with LP Purchase Agreement commitment fee and transaction costs		$ (96,000)									(96,000)
Net loss	(5,457,898)														(5,457,898)
Unrealized gain (loss) on short-term investments	47,697													47,697
Foreign currency translation adjustment	5,497													5,497
Balance at Mar. 31, 2020	21,913,184				$ 51		$ 4,146			197,636,298				48,230	(175,775,541)
Balance, shares at Mar. 31, 2020					51,270		4,146,408
Balance at Dec. 31, 2019	23,969,634						$ 3,873			194,288,368				(4,964)	(170,317,643)
Balance, shares at Dec. 31, 2019							3,872,682
Net loss	(16,580,237)
Unrealized gain (loss) on short-term investments	4,060
Balance at Sep. 30, 2020	16,201,354				$ 24		$ 4,739			203,087,744				6,727	(186,897,880)
Balance, shares at Sep. 30, 2020					23,770		4,738,597
Balance at Mar. 31, 2020	21,913,184				$ 51		$ 4,146			197,636,298				48,230	(175,775,541)
Balance, shares at Mar. 31, 2020					51,270		4,146,408
Stock-based compensation expense	361,477									361,477
Release of restricted stock awards	24						$ 2			22
Release of restricted stock awards, shares							1,583
Net share settlement of restricted stock awards	(2,108)									(2,108)
Net share settlement of restricted stock award, shares							(426)
Stock issued under stock purchase plans	30,512						$ 3			30,509
Stock issued under stock purchase plans, shares							3,033
Issuance of common stock			1,395,058						$ 139			1,394,919
Issuance of common stock, shares									138,981
Conversion of Series A convertible preferred stock for common stock					$ (27)		$ 183			(156)
Conversion of Series A convertible preferred stock for common stock, shares					(27,500)		183,333
Adjustment in connection with LP Purchase Agreement commitment fee and transaction costs		301,538									301,538
Issuance of common stock warrants in connection with SVB Term Loan	420,000									420,000
Net loss	(5,710,551)														(5,710,551)
Unrealized gain (loss) on short-term investments	(26,136)													(26,136)
Foreign currency translation adjustment	909													909
Balance at Jun. 30, 2020	18,683,907				$ 24		$ 4,473			200,142,499				23,003	(181,486,092)
Balance, shares at Jun. 30, 2020					23,770		4,472,912
Stock-based compensation expense	386,911									386,911
Release of restricted stock awards	38						$ 3			35
Release of restricted stock awards, shares							2,542
Net share settlement of restricted stock awards	(3,664)									(3,664)
Net share settlement of restricted stock award, shares							(339)
Employee stock purchase plan expense	5,214									5,214
Issuance of common stock			2,557,012						$ 263			2,556,749
Issuance of common stock, shares									263,482
Net loss	(5,411,788)														(5,411,788)
Unrealized gain (loss) on short-term investments	(17,501)													(17,501)
Foreign currency translation adjustment	1,225													1,225
Balance at Sep. 30, 2020	16,201,354				$ 24		$ 4,739			203,087,744				6,727	(186,897,880)
Balance, shares at Sep. 30, 2020					23,770		4,738,597
Balance at Dec. 31, 2020	14,484,660				$ 24		$ 5,200			205,661,999				5,298	(191,187,861)
Balance, shares at Dec. 31, 2020					23,770		5,199,997
Stock-based compensation expense	337,823									337,823
Release of restricted stock awards	1						$ 1
Release of restricted stock awards, shares							1,390
Net share settlement of restricted stock awards	(1,197)									(1,197)
Net share settlement of restricted stock award, shares							(250)
Employee stock purchase plan expense	13,115									13,115
Issuance of common stock			6,855,198						$ 1,058			6,854,140
Issuance of common stock, shares									1,058,045
Exercise of stock options	326									326
Exercise of stock options, shares							75
Net loss	(4,848,307)														(4,848,307)
Foreign currency translation adjustment	(1,557)													(1,557)
Balance at Mar. 31, 2021	16,840,062				$ 24		$ 6,259			212,866,206				3,741	(196,036,168)
Balance, shares at Mar. 31, 2021					23,770		6,259,257
Balance at Dec. 31, 2020	14,484,660				$ 24		$ 5,200			205,661,999				5,298	(191,187,861)
Balance, shares at Dec. 31, 2020					23,770		5,199,997
Issuance of common stock, shares									2,050,879
Conversion of Series A convertible preferred stock for common stock, shares							144,881
Net loss	(11,953,881)
Unrealized gain (loss) on short-term investments	0
Balance at Sep. 30, 2021	14,887,372				$ 24		$ 7,514			218,018,993				2,583	(203,141,742)
Balance, shares at Sep. 30, 2021					23,770		7,513,733
Balance at Mar. 31, 2021	16,840,062				$ 24		$ 6,259			212,866,206				3,741	(196,036,168)
Balance, shares at Mar. 31, 2021					23,770		6,259,257
Stock-based compensation expense	339,369									339,369
Release of restricted stock awards	1						$ 1
Release of restricted stock awards, shares							992
Net share settlement of restricted stock awards	(695)									(695)
Net share settlement of restricted stock award, shares							(127)
Employee stock purchase plan expense	13,116									13,116
Stock issued under stock purchase plans	53,437						$ 13			53,424
Stock issued under stock purchase plans, shares							13,637
Issuance of common stock			$ 3,810,621						$ 993			$ 3,809,628
Issuance of common stock, shares									992,834
Exercise of pre-funded warrants							$ 145			(145)
Exercise of pre-funded warrants, shares							144,881
Net loss	(2,614,952)														(2,614,952)
Foreign currency translation adjustment	(145)													(145)
Balance at Jun. 30, 2021	18,440,814				$ 24		$ 7,411			217,080,903				3,596	(198,651,120)
Balance, shares at Jun. 30, 2021					23,770		7,411,474
Stock-based compensation expense	323,172									323,172
Release of restricted stock awards	2						$ 2
Release of restricted stock awards, shares							1,158
Net share settlement of restricted stock awards	(679)									(679)
Net share settlement of restricted stock award, shares							(117)
Employee stock purchase plan expense	15,719									15,719
Issuance of common stock		$ 599,979						$ 101			$ 599,878
Issuance of common stock, shares								101,218
Net loss	(4,490,622)														(4,490,622)
Unrealized gain (loss) on short-term investments	0
Foreign currency translation adjustment	(1,013)													(1,013)
Balance at Sep. 30, 2021	$ 14,887,372				$ 24		$ 7,514			$ 218,018,993				$ 2,583	$ (203,141,742)
Balance, shares at Sep. 30, 2021					23,770		7,513,733

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Changes in Stockholders' Equity (Parenthetical) - USD ($)	3 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020
Statement Of Stockholders Equity [Abstract]
At the market offering, commissions and issuance costs	$ 100,000	$ 200,000	$ 79,000	$ 43,000	$ 200,000
Private placement issuance costs					$ 37,000

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Operating activities
Net loss	$ (11,953,881)	$ (16,580,237)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	568,380	1,039,989
Accretion of discount on NuvoGen obligation	(9,206)	(9,771)
Provision for excess inventory	60,143	5,649
Amortization of QNAH Convertible Note issuance costs		6,505
Amortization of MidCap Credit Facility discount and issuance costs		101,482
Amortization of SVB Term Loan discount and issuance costs	351,068	121,168
Stock-based compensation expense	1,000,368	1,163,742
Employee stock purchase plan expense	41,950	15,972
Non-cash operating lease expense	359,014	465,504
Accrued interest on available-for-sale securities investments	(18,394)	(101,996)
Stock compensation expense in connection with LP Purchase Agreement		205,538
Gain on forgiveness of PPP Loan	(1,735,792)
Loss on extinguishment of Midcap Credit Facility and QNAH Convertible Note		522,394
Loss on abandonment and disposal of assets, net	178,925	77,498
Changes in operating assets and liabilities:
Accounts receivable	(597,489)	1,793,975
Inventory	(892,655)	(255,718)
Prepaid expenses and other	(300,469)	457,504
Deferred offering costs		140,320
Accounts payable	(50,230)	(778,706)
Accrued liabilities	205,015	(474,521)
Contract liabilities	53,062	(74,700)
Operating lease liabilities	(378,355)	(583,828)
Net cash used in operating activities	(13,118,546)	(12,742,237)
Investing activities
Purchase of property and equipment	(590,736)	(418,712)
Maturities of available-for-sale securities	9,000,000	25,450,000
Purchase of available-for-sale securities	(17,871,203)	(11,565,882)
Net cash (used in) provided by investing activities	(9,461,939)	13,465,406
Financing activities
Proceeds from issuance of SVB Term Loan		10,000,000
Payment of SVB Term Loan issuance costs		(115,193)
Proceeds from ATM Offering, net of commissions of $0.3 million	10,665,819	6,387,982
Proceeds from LP Purchase Agreement	599,979
Proceeds from PPP Loan		1,717,000
Proceeds from Series A convertible preferred stock in private placement		562,955
Payments on NuvoGen obligation	(379,431)	(539,323)
Proceeds from exercise of pre-funded warrants		31,768
Proceeds from shares purchased under stock purchase plans	53,437	25,133
Payments on financing leases	(18,040)	(32,553)
Proceeds from exercise of stock options	326
Taxes paid for net share settlement of restricted stock awards	(2,571)	(12,824)
Payments on 2021 and 2020 Insurance Notes	(494,352)	(324,301)
Net cash provided by financing activities	10,425,167	7,262,021
Effect of exchange rates on cash	(12,848)	9,283
Increase (decrease) in cash, cash equivalents and restricted cash	(12,168,166)	7,994,473
Cash, cash equivalents and restricted cash at beginning of period	22,397,812	10,889,995
Cash, cash equivalents and restricted cash at end of period	10,229,646	18,884,468
Supplemental disclosure of noncash investing and financing activities
Issuance of Series A convertible preferred stock in exchange for outstanding common stock		2,424,900
Issuance of common stock upon conversion of Series A convertible preferred stock		1,622,500
Issuance of common stock from cashless exercise of pre-funded warrants	145
Operating lease right-of-use assets obtained in exchange for operating lease liabilities	1,302,457	21,078
Carrying value of demonstration units transferred from property and equipment to inventory	16,128	18,817
2021 and 2020 Insurance Notes issued for insurance premiums	746,360	735,195
Gain on forgiveness of PPP Loan	1,735,792
Supplemental cash flow information
Cash paid for interest	450,344	719,676
Cash paid for taxes	$ 12,665	9,961
QNAH Convertible Note
Financing activities
Payments for extinguishment of debt		(3,000,000)
MidCap Credit Facility
Financing activities
Payments for extinguishment of debt		$ (7,438,623)

Condensed Consolidated Statem_6

Condensed Consolidated Statements of Cash Flows (Parenthetical) $ in Millions	9 Months Ended
	Sep. 30, 2021USD ($)
ATM Offering
Underwriting discounts, commissions and issuance costs	$ 0.3

Description of Business, Basis

Description of Business, Basis of Presentation and Principles of Consolidation	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Description of Business, Basis of Presentation and Principles of Consolidation	Note 1. Description of Business, Basis of Presentation and Principles of Consolidation HTG Molecular Diagnostics, Inc. (the “Company”) is a life science company whose mission is to advance precision medicine through its innovative transcriptome-wide profiling technology. The Company derives revenue from sales of its HTG EdgeSeq instrument system and integrated next-generation sequencing-based (“NGS-based”) HTG EdgeSeq assays, from sample processing and custom research use only (“RUO”) assay design services and from collaborative development services. The Company operates in one segment and its customers are located primarily in the United States and Europe. For the three and nine months ended September 30, 2021 approximately 24% and 30% respectively, of the Company’s revenue was generated from sales originated by customers located outside of the United States, compared with 19% and 31% for the three and nine months ended September 30, 2020, respectively. COVID-19 Pandemic The full impact of the COVID-19 pandemic (“COVID-19”) continues to evolve as of the date of this report and management continues to actively monitor the potential impact of the global situation on its financial condition, liquidity and future results of operations, suppliers, industry and workforce. Given the ongoing evolution of COVID-19, including the emergence of variants and resurgences in many areas of the world and the global responses to curb its spread, the Company is not able to fully estimate the effects of COVID-19 on its results of operations, financial condition or liquidity. The Company experienced a significant slowing of product and product-related services revenue generation beginning in March 2020 and continuing throughout 2020 and the three quarters of 2021. The extent of this impact has varied from customer to customer depending upon how they have been directly or indirectly impacted by local stay-at-home orders and other social distancing measures, prioritization by those customers as the immediate impacts of the pandemic have passed, and the workforce and supplier impacts that COVID-19 has had on each customer. In March 2020, the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) was enacted in response to COVID-19. On April 21, 2020, the Company received proceeds from a loan pursuant to the Paycheck Protection Program (“PPP”) of the CARES Act (the “PPP Loan”) in the amount of $1.7 million from Silicon Valley Bank (“SVB”), as lender (see Note 8). The Company applied for full forgiveness of the PPP Loan in October 2020. In May 2021, the Company received notification that the PPP Loan and related accrued interest, totaling $1,735,792, were forgiven by the U.S. Small Business Administration (“SBA”), and that the PPP Loan note had been canceled. In December 2020, the Consolidated Appropriations Act (the “Appropriations Act”) was signed into law to further address the ongoing impacts of COVID-19. The Appropriations Act introduced several additional potential credits and benefits for employers to consider applying for, including, but not limited to, the ability for employers who have previously obtained a PPP Loan to potentially also qualify for Employee Retention Credits (“ERC”), initially created as part of the CARES Act. In March 2021, the American Rescue Plan of 2021 was enacted to, amongst other things, extend and expand ERC benefits through December 31, 2021. The Company has qualified for certain ERC benefits during the year ended December 31, 2020 and the first three quarters of 2021 and expects to continue to seek out these benefits in future periods as appropriate. ERC benefits of approximately $0.6 million and $1.7 million were included in operating expenses as an offset to the related compensation costs in the accompanying condensed consolidated statements of operations for the three and nine months ended September 30, 2021, respectively. While there remains uncertainty as to the ultimate impact of COVID-19, the Company has considered the known impacts on its business as of the date these condensed consolidated financial statements were issued and has reflected any known or expected impacts in its condensed consolidated financial statements, including consideration of potential impairment risks to its long-lived assets, potential accounts receivable collection risks and potential impacts to its overall liquidity position. Basis of Presentation The accompanying condensed consolidated financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and reflect the accounts of the Company as of September 30, 2021 and for the three and nine months ended September 30, 2021 and 2020. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America (“GAAP”) for complete financial statements. The accompanying condensed consolidated financial statements reflect all normal recurring adjustments which, in the opinion of management, are necessary for a fair statement of the Company’s financial position and the results of its operations and cash flows, as of and for the periods presented. The accompanying condensed consolidated balance sheet at December 31, 2020 has been derived from the audited consolidated financial statements at that date but does not include all of the information and disclosures required by GAAP for annual financial statements. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the full year. These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto for the year ended December 31, 2020, included in the Company’s Annual Report on Form 10-K filed with the SEC on March 25, 2021. All share and per share amounts within the condensed consolidated financial statements and notes thereto have been adjusted to reflect the reverse stock split completed by the Company in November 2020 for all periods and dates presented. See Note 14 for more information about the Company’s reverse stock split. Going Concern and Management has assessed the Company’s ability to continue as a going concern within one year of issuance of these financial statements. The accompanying interim unaudited condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of the assets and satisfaction of liabilities in the normal course of business. However, the Company has had recurring operating losses and negative operating cash flows since its inception and has an accumulated deficit of $203.1 million as of September 30, 2021. As of September 30, 2021, the Company had working capital of $23.7 million and long-term liabilities of $11.5 million. The Company’s liability balances consist primarily of its debt obligations, including an asset-secured loan with Silicon Valley Bank (the “SVB Term Loan”), as well as an obligation to NuvoGen Research, LLC (the “NuvoGen obligation”) (see Note 10). Potentially changing circumstances, including COVID-19 uncertainties, may result in the depletion of the Company’s capital resources more rapidly than it currently anticipates, resulting in the Company not having adequate resources to fund its planned operations and expenditures for at least the next 12 months and to comply with the financial covenant in the Loan and Security Agreement for the SVB Term Loan (the “Loan Agreement”). These circumstances raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying condensed consolidated financial statements do not include any adjustments that may result from the outcome of these uncertainties. The Company will need to raise additional capital to fund its operations and service its long-term debt obligations until its revenue reaches a level sufficient to provide for self-sustaining cash flows. There can be no assurance that additional capital will be available on acceptable terms, or at all, or that the Company’s revenue will reach a level sufficient to provide for self-sustaining cash flows. In addition, the Company must comply with a financial covenant in the SVB Term Loan requiring the Company to maintain unrestricted cash of not less than the greater of (i) $12.5 million and (ii) an amount equal to six times the amount of the Company’s average monthly Cash Burn (as defined in the Loan Agreement) over the trailing three months. Principles of Consolidation The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, HTG Molecular Diagnostics France, SARL, after elimination of all intercompany transactions and balances as of September 30, 2021 and December 31, 2020. Concentration Risks Financial instruments that potentially subject the Company to credit risk consist principally of cash and cash equivalents and accounts receivable. The Company maintains the majority of its cash balances in the form of cash deposits in bank checking and money market accounts in amounts in excess of federally insured limits. Management believes, based upon the quality of the financial institution, that the credit risk with regard to these deposits is not significant. The Company sells its instrument, related consumables, sample processing services, custom RUO assay design and collaborative development services primarily to biopharmaceutical companies, academic institutions and molecular labs. The Company routinely assesses the financial strength of its customers and credit losses have been minimal to date. The Company’s top two customers accounted for 27% and 13% of the Company’s total revenue for the three months ended September 30, 2021, compared with the Company’s top two customers accounting for 24% and 10% of the Company’s total revenue for the three months ended September 30, 2020. The Company’s top two customers accounted for 23% and 12% of the Company’s total revenue for the nine months ended September 30, 2021, compared with the Company’s top two customer accounting for 16% and 10% of the Company’s total revenue for the nine months ended September 30, 2020. The largest two customers accounted for 52% and 11% of the Company’s accounts receivable as of September 30, 2021. The largest two customers accounted for approximately 9% each of the Company’s accounts receivable as of December 31, 2020. Three vendors accounted for 26%, 14% and 10% of the Company’s accounts payable as of September 30, 2021, compared with two vendors who accounted for 21% and 20% of the Company’s accounts payable as of December 31, 2020. The Company currently relies on a single supplier to produce a subcomponent used in its HTG EdgeSeq processors. A loss of this supplier could significantly delay the delivery of processors, which in turn could materially affect the Company’s ability to generate revenue.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2. Summary of Significant Accounting Policies Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The Company’s estimates include revenue recognition, stock-based compensation expense, bonus and warranty accrual, income tax valuation allowances and reserves, recovery of long‑lived assets, lease liability, inventory obsolescence and valuation of inventory, accounts receivable and available-for-sale securities. Actual results could materially differ from those estimates, especially in light of the significant uncertainty that remains as to the full impact of COVID-19 on the Company’s operations, as well as those of its workforce, supply chains, distribution networks and those of its customers. Significant Accounting Policies There have been no material changes in the Company’s significant accounting policies from those previously disclosed in the consolidated financial statements included in the Company’s Annual Report on Form 10-K, filed with the SEC on March 25, 2021. Fair Value of Financial Instruments The carrying value of financial instruments classified as current assets and current liabilities approximate fair value due to their liquidity and short-term nature. Investments that are classified as available-for-sale are recorded at fair value, which is determined using quoted market prices, broker or dealer quotations or alternative pricing sources with reasonable levels of price transparency. The carrying value of the SVB Term Loan (see Note 8) is estimated to approximate its fair value as the interest rate approximates the market rate for debt with similar terms and risk characteristics. The NuvoGen obligation relates to an asset purchase transaction with a then-common stockholder of the Company (see Note 10). As of September 30, 2021, the estimated aggregate fair value of the NuvoGen obligation is approximately $4.7 million, determined using a Monte Carlo simulation with key assumptions including future revenue, volatility, discount and risk-free rates. Recently Adopted Accounting Pronouncements In October 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Codification (“ASC” or the “FASB Codification”) Update (“ASU”) No. 2020-10, Codification Improvements (“Update No. 2020-10”), which amended a variety of topics in the FASB Codification in order to improve the consistency of the Codification and the application thereof, while leaving GAAP unchanged. Update No. 2020-10 was effective for fiscal years beginning after December 15, 2020 for public business entities. The Company’s adoption of this standard on January 1, 2021 did not have a material impact on its condensed consolidated financial statements or related footnote disclosures. In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes New Accounting Pronouncements The following are new FASB ASUs that had not been adopted by the Company as of September 30, 2021: In August 2020, the FASB issued ASU No. 2020-06, Debt – Debt with Conversion and other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and also simplifies the diluted earnings per share calculation in certain areas. The standard is effective for public business entities, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years and interim periods within those fiscal years, beginning after December 15, 2021. For all other entities, the standard will be effective for fiscal years beginning after December 15, 2023. Early adoption is permitted, and adoption must be as of the beginning of the Company’s annual fiscal year. The Company is currently evaluating the impact of this standard on its consolidated financial statements and related disclosures. In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses

Inventory

Inventory	9 Months Ended
	Sep. 30, 2021
Inventory Disclosure [Abstract]
Inventory	Note 3. Inventory Inventory, net of allowance, consisted of the following as of the dates indicated: September 30, December 31, 2021 2020 Raw materials $ 1,662,205 $ 1,079,528 Work in process 235,637 147,455 Finished goods 459,317 291,195 Total gross inventory 2,357,159 1,518,178 Less inventory allowance (16,393 ) (26,052 ) $ 2,340,766 $ 1,492,126 For the three and nine months ended September 30, 2021, the Company recorded adjustments to provision for excess inventory of $54,636 and $60,143, respectively. For the three and nine months ended September 30, 2020, the Company recorded adjustments to provision for excess inventory of $10,530 and $12,202, respectively. Adjustments in these periods to the allowance for estimated shrinkage, obsolescence and excess inventory have been included in cost of product and product-related services revenue in the accompanying condensed consolidated statements of operations. HTG EdgeSeq instruments at customer locations under evaluation agreements are included in finished goods inventory. Finished goods inventory under evaluation as of September 30, 2021 was $169,042 compared with $50,855 as of December 31, 2020.

Fair Value Instruments

Fair Value Instruments	9 Months Ended
	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Fair Value Instruments	Note 4. Fair Value Instruments Financial assets and liabilities measured at fair value are classified in their entirety in the fair value hierarchy based on the lowest level input significant to the fair value measurement. The following table classifies the Company’s financial assets and liabilities measured at fair value on a recurring basis as of September 30, 2021 and December 31, 2020 in the fair value hierarchy: September 30, 2021 Level 1 Level 2 Level 3 Total Asset included in: Cash and cash equivalents Money market securities $ 10,055,376 $ — $ — $ 10,055,376 Investments available-for-sale at fair value Corporate debt securities — 15,187,672 — 15,187,672 Total $ 10,055,376 $ 15,187,672 $ — $ 25,243,048 December 31, 2020 Level 1 Level 2 Level 3 Total Asset included in: Cash and cash equivalents Money market securities $ 17,497,282 $ — $ — $ 17,497,282 Corporate debt securities — 4,499,270 — 4,499,270 Investments available-for-sale at fair value Corporate debt securities — 6,298,075 — 6,298,075 Total $ 17,497,282 $ 10,797,345 $ — $ 28,294,627 There are no other financial instruments subject to fair value measurement on a recurring basis. Transfers to and from Levels 1, 2 and 3 are recognized at the end of the reporting period. There were no transfers between levels for the three and nine months ended September 30, 2021 or the year ended December 31, 2020. Level 1 instruments include investments in money market funds. These instruments are valued using quoted market prices for identical unrestricted instruments in active markets. The Company defines active markets for debt instruments based on both the average daily trading volume and the number of days with trading activity. Level 2 instruments include corporate debt securities, including commercial paper and corporate bonds. Valuations of Level 2 instruments can be verified to quoted prices, recent trading activity for identical or similar instruments, broker or dealer quotations or alternative pricing sources with reasonable levels of price transparency. Consideration is given to the nature of the quotations (e.g., indicative or firm) and the relationship of recent market activity to the prices provided from alternative pricing sources. Fair values of these assets are based on prices provided by independent market participants that are based on observable inputs using market-based valuation techniques. These valuation models and analytical tools use market pricing or similar instruments that are both objective and publicly available, including matrix pricing or reported trades, benchmark yields, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids and/or offers. The Company did not adjust any of the valuations received from these third parties with respect to any of its Level 1 or 2 securities for the nine-month period ended September 30, 2021 or the year ended December 31, 2020 and did not have any Level 3 financial assets or liabilities during either of these periods.

Available-for-Sale Securities

Available-for-Sale Securities	9 Months Ended
	Sep. 30, 2021
Investments Debt And Equity Securities [Abstract]
Available-for-Sale Securities	Note 5. Available-for-Sale Securities The Company’s portfolio of available-for-sale securities consists of high credit quality corporate debt securities. The following is a summary of the Company’s available-for-sale securities as of September 30, 2021 and December 31, 2020: September 30, 2021 Gross Gross Fair Value Amortized Unrealized Unrealized (Net Carrying Cost Gains Losses Amount) Corporate debt securities 15,187,672 — — 15,187,672 Total available-for-sale securities $ 15,187,672 $ — $ — $ 15,187,672 December 31, 2020 Gross Gross Fair Value Amortized Unrealized Unrealized (Net Carrying Cost Gains Losses Amount) Corporate debt securities 6,298,075 — — 6,298,075 Total available-for-sale securities $ 6,298,075 $ — $ — $ 6,298,075 There were no gross unrealized losses relating to the Company’s available-for-sale securities investments as of September 30, 2021. There were no net adjustments to unrealized gains (losses) on short-term investments, net of tax in other comprehensive income for the three and nine months ended September 30, 2021. The net adjustment to unrealized gains (losses) on short-term investments, net of tax in other comprehensive income totaled $(17,501) and $4,060 for the three and nine months ended September 30, 2020, respectively. Contractual maturities of debt investment securities as of September 30, 2021 are shown below. Expected maturities may differ from contractual maturities where issuers of the securities have the right to prepay obligations without prepayment penalties. Under 1 Year 1 to 2 Years Total Corporate debt securities 15,187,672 — 15,187,672 Total available-for-sale securities $ 15,187,672 $ — $ 15,187,672

Property and Equipment

Property and Equipment	9 Months Ended
	Sep. 30, 2021
Property Plant And Equipment [Abstract]
Property and Equipment	Note 6. Property and Equipment Property and equipment, net, consists of the following as of the dates indicated: September 30, December 31, 2021 2020 Furniture & fixtures $ 1,086,341 $ 1,082,717 Leasehold improvements 1,931,762 1,943,534 Equipment used in manufacturing 2,673,452 2,166,743 Equipment used in research & development 2,506,644 2,506,644 Equipment used in the field 182,762 208,005 Software 488,098 420,301 Property and equipment 8,869,059 8,327,944 Less: accumulated depreciation and amortization (7,649,869 ) (7,100,542 ) $ 1,219,190 $ 1,227,402 Depreciation and leasehold improvement amortization expense was approximately $0.2 million and $0.6 million for the three and nine months ended September 30, 2021, respectively, and $0.3 million and $1.0 million for the three and nine months ended September 30, 2020, respectively.

Accrued Liabilities

Accrued Liabilities	9 Months Ended
	Sep. 30, 2021
Accrued Liabilities Current [Abstract]
Accrued Liabilities	Note 7. Accrued Liabilities Accrued liabilities consisted of the following as of the dates indicated: September 30, December 31, 2021 2020 Accrued employee bonuses $ 775,219 $ 436,799 Payroll and employee benefit accruals 414,177 694,058 Accrued product warranty 92,696 92,696 Other accrued liabilities 326,909 236,325 $ 1,609,001 $ 1,459,878

Debt Obligations

Debt Obligations	9 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
Debt Obligations	Note 8. Debt Obligations Current portion of long-term debt consisted of the following as of the dates indicated: September 30, December 31, 2021 2020 SVB Term Loan $ 3,750,000 $ 2,000,000 PPP Loan — 857,040 2021 Insurance Note 417,107 — 2020 Insurance Note — 165,099 $ 4,167,107 $ 3,022,139 Long-term debt, net of current portion, discount and debt issuance costs, consisted of the following as of the dates indicated: September 30, December 31, 2021 2020 SVB Term Loan, net of discount and debt issuance costs $ 6,309,416 $ 7,708,348 PPP Loan — 859,960 $ 6,309,416 $ 8,568,308 SVB Term Loan On June 24, 2020 (the “Closing Date”), the Company entered into the SVB Term Loan, by and among the Company and SVB, as lender, which provides a secured term loan in the principal amount of $10.0 million. The proceeds from the SVB Term Loan were fully funded on June 25, 2020. Together with cash on hand, the proceeds were used to repay in full all outstanding amounts and fees due under the Company’s credit facility with MidCap Financial Trust (the “MidCap Credit Facility”) in an aggregate amount equal to $7.5 million, including collateral agent legal fees and prepayment fees, in addition to the Company’s subordinated convertible promissory note to QNAH (the “QNAH Convertible Note”) and related accrued interest in the aggregate amount of $3.2 million. As a result of the repayment, the Company recorded a loss on extinguishment of the MidCap Credit Facility and the QNAH Convertible Note of $0.5 million in other income (expense) in the accompanying condensed consolidated statements of operations for the nine months ended September 30, 2020. All obligations under the MidCap Credit Facility and the QNAH Convertible Note were fulfilled as a result of this extinguishment. The SVB Term Loan bears interest at a floating rate equal to the greater of 2.50% above the Prime Rate (as defined in the Loan Agreement) and 5.75%. Interest on the SVB Term Loan is due and payable monthly in arrears. The SVB Term Loan originally required interest-only payments through June 30, 2021. As a result of the Company’s achievement of an equity milestone defined in the Loan Agreement during the quarter ended June 30, 2021, the interest-only period has been extended for six months. The extended interest-only period will be followed by equal monthly payments of principal and interest through the maturity date of December 1, 2023. The Company’s obligations under the Loan Agreement are secured by a security interest in substantially all of its assets, excluding intellectual property (which is subject to a negative pledge), and the Company’s future subsidiaries, if any, may be required to become co-borrowers or guarantors under the Loan Agreement. In addition, the Company must comply with a financial covenant in the SVB Term Loan requiring the Company to maintain unrestricted cash of not less than the greater of (i) $ 12.5 million and (ii) an amount equal to six times the amount of the Company’s average monthly Cash Burn (as defined in the Loan Agreement) over the trailing three months. In connection with the Loan Agreement, the Company granted to SVB a warrant to purchase up to 42,894 shares of the Company’s common stock at a purchase price of $11.6565 per share. The warrant will expire on June 24, 2030 and may be exercised for cash or at the election of the holder on a cashless, net exercise basis. The fair value of the warrant on the date of issuance was approximately $0.4 million, determined using the Black-Scholes option-pricing model, and was recorded as a discount to the SVB Term Loan, with a corresponding credit to additional paid in capital since the warrant met the requirements to be classified as equity. The Company included $0.7 million and $1.1 million of debt discount associated with the SVB Term Loan, resulting from fees and debt issuance costs, inclusive of the fair value of warrants issued, in long-term debt, net of current portion, discount and debt issuance costs in the as of September 30, 2021 and December 31, 2020, respectively. Amortization of the debt discount associated with the SVB Term Loan was $0.1 million and $0.4 million for the three and nine months ended September 30, 2021, respectively, compared to $0.1 million for the three and nine months ended September 30, 2020, respectively, and was included in interest expense in the . The remaining principal repayments due under the SVB Term Loan as of September 30, 2021 are as follows for each fiscal year: 2021 $ - 2022 5,000,000 2023 5,000,000 Total SVB Term Loan payments 10,000,000 Less discount and deferred financing costs (740,584 ) Plus final fee premium 800,000 Total SVB Term Loan, net $ 10,059,416 Paycheck Protection Program Loan On April 21, 2020, the Company received proceeds from a loan in the amount of $1.7 million from SVB, as lender, pursuant to the PPP. The PPP Loan was evidenced by a promissory note, which bore interest at an annual rate of 1%, and contained customary events of default relating to, among other things, payment defaults and breaches of representations, warranties or terms of the PPP Loan documents. Under the CARES Act and PPP Flexibility Act, loan forgiveness was available for the sum of documented payroll costs (including benefits), rent and utility obligations, and interest on certain of the Company’s other debt obligations incurred during the 24-week period beginning on the date of loan approval, as defined by the applicable guidelines and the SBA. The Company applied for full PPP Loan forgiveness in October 2020. On May 26, 2021 the Company received notification from SVB that the PPP Loan and related accrued interest was forgiven in full by the SBA, and the PPP Loan note had been canceled. Accordingly, the Company recorded a gain on forgiveness of the PPP Loan of $0 and $1.7 million for the three and nine months ended September 30, 2021, included in other income (expense) in the accompanying condensed consolidated statements of operations . The Company has . Insurance Note On April 27, 2020, the Company entered into a commercial financing agreement to extend the payment period related to its director and officer insurance policy (the “2020 Insurance Note”). The 2020 Insurance Note required a down payment to be made upon signing the agreement equal to approximately $0.2 million. The unpaid premium balance of approximately $0.7 million was financed at an annual rate of 3.61% and was repaid in nine equal monthly payments of principal and interest through February 2021 On May 5, 2021, the Company entered into a new commercial financing agreement to extend the payment period related to its director and officer insurance policy (the “2021 Insurance Note”). The 2021 Insurance Note required a down payment to be made upon signing the agreement equal to approximately $0.4 million. The remaining unpaid premium balance of approximately $0.7 million has been financed at an annual rate of 3.57% and is to be repaid in nine equal monthly payments of principal and interest beginning in June 2021

Revenue from Contracts with Cus

Revenue from Contracts with Customers	9 Months Ended
	Sep. 30, 2021
Revenue From Contract With Customer [Abstract]
Revenue from Contracts with Customers	Note 9. Revenue from Contracts with Customers Product and Product-related Services Revenue The Company had product and product-related services revenue consisting of revenue from the sale of instruments and consumables and the use of the HTG EdgeSeq proprietary technology to process samples and design custom RUO assays for the three and nine months ended September 30, 2021 and 2020 as follows: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Product revenue: Instruments $ 407,130 $ 71,742 $ 1,028,348 $ 563,396 Consumables 793,542 764,605 2,265,894 2,091,848 Total product revenue 1,200,672 836,347 3,294,242 2,655,244 Product-related services revenue: Custom RUO assay design — 238,502 48,350 1,210,968 RUO sample processing 1,319,738 626,219 2,687,168 1,551,519 Total product-related services revenue 1,319,738 864,721 2,735,518 2,762,487 Total product and product-related services revenue $ 2,520,410 $ 1,701,068 $ 6,029,760 $ 5,417,731 As the Company’s agreements for product and product-related services revenue have an expected duration of one year or less, the Company has elected the practical expedient in ASC 606-10-50-14(a) to not disclose information about its remaining performance obligations. Sale of Instruments and Consumables The delivery of each instrument and the related installation and calibration are considered to be a single performance obligation, as the HTG EdgeSeq instrument must be professionally installed and calibrated prior to use. Instrument product revenue is generally recognized upon installation and calibration of the instrument by field service engineers, which represents the point at which the customer has the ability to use the instrument and has accepted the asset. Installation generally occurs within one month of instrument shipment. The delivery of each consumable is a separate performance obligation. Consumables revenue is recognized upon transfer of control, which represents the point when the customer has legal title and the significant risks of ownership of the asset. The Company’s standard terms and conditions provide that no right of return exists for instruments and consumables, unless replacement is necessary due to delivery of defective or damaged product. Customer payment terms vary but are typically between 30 and 90 days of revenue being earned from shipment or delivery, as applicable. The Company provides instruments to certain customers under reagent rental agreements. Under these agreements, the Company installs an instrument in the customer’s facility without a fee and the customer agrees to purchase consumable products at a stated price over the term of the agreement; in some instances, the agreements do not contain a minimum purchase requirement. Terms range from several months to multiple years and may automatically renew in several month or multiple year increments unless either party notifies the other in advance that the agreement will not renew. The Company measures progress toward complete satisfaction of this performance obligation to provide the instrument and deliver the consumables using an output method based on the number of consumables delivered in relation to the total consumables to be provided under the reagent rental agreement. This is considered to be representative of the delivery of outputs under the arrangement and the best measure of progress because the customer benefits from the instrument only in conjunction with the consumables. The Company expects to recover the cost of the instrument under the agreement through the fees charged for consumables, to the extent sold, over the term of the agreement. RUO Sample Processing The Company also provides sample preparation and processing services and molecular profiling of retrospective cohorts for its customers through its VERI/O laboratory, whereby the customer provides samples to be processed using HTG EdgeSeq technology specified in the order. Customers are charged a per sample fee for sample processing services which is recognized as revenue upon delivery of a data file to the customer showing the results of testing and completing delivery of the agreed upon service. This is when the customer can use and benefit from the results of testing and the Company has the present right to payment. Custom RUO Assay Design and Related Agreements The Company enters into custom RUO assay design agreements that may generate up-front fees and subsequent payments that might be earned upon completion of design process phases. The Company measures progress toward complete satisfaction of its performance obligation to perform custom RUO assay design using an output method based on the costs incurred to date compared with total expected costs, as this is representative of the delivery of outputs under the arrangements and the best measure of progress. However, because in most instances the assay design fees are contingent upon completion of each phase of the design project and the decision of the customer to proceed to the next phase, the amount to be included in the transaction price and recognized as revenue is limited to that which the customer is contractually obligated to pay upon completion of that phase, which is when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. Collaborative Development Services Revenue The Company enters into collaborative development services agreements with biopharmaceutical companies for the development of NGS-based companion diagnostic assays in support of and in conjunction with, biopharmaceutical companies’ drug development programs. These collaborative development services agreements may generate upfront fees, and in some cases subsequent milestone payments that may be earned upon completion of certain product development milestones or activities. The Company follows ASC 606 and ASC 808 to determine the appropriate recognition of revenue under its collaborative research, development and commercialization agreements. Because each SOW had an expected duration of one year or less, the Company elected the practical expedient in ASC 606-10-50-14(a) not to disclose information about its remaining performance obligations for each SOW. Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Collaborative development services $ — $ 76,030 $ — $ 548,135 For the three and nine months ended September 30, 2020, collaborative development services revenue was generated through statements of work entered into a Master Assay Development, Commercialization and Manufacturing Agreement (the “Governing Agreement”) with QIAGEN Manchester Limited (“QML”). Under these agreements, the Companies combined technological and commercial strengths to offer biopharmaceutical companies a complete NGS-based solution for the development, manufacture and commercialization of companion diagnostic assays in support of and in conjunction with, biopharmaceutical companies’ drug development programs. Remaining agreed upon procedures associated with these statements of work were completed in the prior year and no additional collaborative development services programs have been entered into as of September 30, 2021. Contract Liabilities The Company may receive up-front payments from customers for custom RUO assay design and sample processing services. In addition, payments for instrument extended warranty contracts are required to be made in advance. The Company recognizes such up-front payments as contract liabilities. The contract liabilities are subsequently reduced as revenue is recognized. Contract liabilities of approximately $0.2 million were included in contract liabilities – current and an additional immaterial amount of contract liabilities were included in other non-current liabilities in the accompanying condensed consolidated balance sheets as of September 30, 2021, reflecting the period in which the Company expects to realize the deferred revenue. Changes in the Company’s contract liability were as follows as of the dates indicated: Product Revenue Custom RUO Assay Design Sample Processing Total Contract Liability Balance at January 1, 2021 $ 103,580 $ - $ 93,884 $ 197,464 Deferral of revenue 261,100 — 525,899 786,999 Recognition of deferred revenue (198,438 ) — (535,501 ) (733,939 ) Balance at September 30, 2021 $ 166,242 $ — $ 84,282 $ 250,524 Product Revenue Custom RUO Assay Design Sample Processing Total Contract Liability Balance at January 1, 2020 $ 95,148 $ 66,216 $ 438,090 $ 599,454 Deferral of revenue 335,265 459,385 77,104 871,754 Recognition of deferred revenue (325,181 ) (525,601 ) (95,670 ) (946,452 ) Balance at September 30, 2020 $ 105,232 $ — $ 419,524 $ 524,756

Other Agreements

Other Agreements	9 Months Ended
	Sep. 30, 2021
Other Agreements [Abstract]
Other Agreements	Note 10. Other Agreements NuvoGen Obligation Pursuant to the Company’s asset purchase agreement with NuvoGen Research, LLC (“NuvoGen”), as amended, the Company is obligated to pay NuvoGen annually the greater of $400,000 or 6% of annual revenue until the obligation is paid in full. In addition to fixed quarterly payments of $100,000, there were $51,225 of revenue-based payments payable as of September 30, 2021, compared with approximately $54,777 of revenue-based payments payable as of December 31, 2020. There have been no significant modifications to the terms and conditions of the Company’s NuvoGen obligation since the disclosures made in Part II, Item 8, Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K, filed with the SEC on March 25, 2021. Remaining minimum payments to be made in 2021 include $51,225 of revenue-based payments payable as of September 30, 2021 and the fourth quarter 2021 minimum payment. Minimum payments for 2022 include an estimate of additional revenue-based payments to be made in the first, second and third quarters of 2022 relating to revenue generated in the fourth quarter of 2021 and the first and second quarters of 2022, estimated using actual revenue generated in the same quarters in 2020 and 2021. Remaining minimum payments include only the minimum quarterly payments to be made in each period. Actual payments could vary from what is shown in the table, to the extent that 6% of the Company’s annual revenue in 2022 and beyond exceeds $400,000. The remaining minimum payments to be made to NuvoGen as of September 30, 2021 are as follows for each fiscal year: 2021 $ 151,225 2022 479,432 2023 400,000 2024 400,000 2025 400,000 2026 and beyond 2,702,661 Total NuvoGen obligation payments 4,533,318 Plus interest accretion 70,170 Total NuvoGen obligation, net $ 4,603,488 The Company has recorded the obligation at the estimated present value of the future payments using a discount rate of 2.5%, the Company’s estimate of its effective borrowing rate for similar obligations. The unamortized interest accretion was $(70,170) and $(79,376)

Leases

Leases	9 Months Ended
	Sep. 30, 2021
Leases [Abstract]
Leases	Note 11. Leases Operating Leases T he Company leases office space under agreements classified as operating leases. The Company’s active leases as of September 30, 2021 are for office and manufacturing space in Tucson, Arizona, which expire in 2025. The Company’s leases do not include any contingent rental payments, impose any financial restrictions, or contain any residual value guarantees. The Company amended its Tucson facility leases in December 2020 to extend the terms of the leases for one year, through January 31, 2022 and again in September 2021 to extend the terms of the leases for three years, through January 31, 2025. The lease extensions were treated as lease modifications for accounting purposes, and allow for an additional extension of two years on the same terms and conditions of the existing amended lease agreement, except that the lease rates would be adjusted to reflect lease rates applicable to like-kind buildings within the market at the time that the Company elects to exercise the extension options, but in no event less than the last applicable rental rate. The Company has not accounted for these renewal options in the calculation of the lease liabilities and right-of-use assets as the Company is not reasonably certain to exercise the options. In the first quarter of 2021, the Company closed its development laboratory in San Carlos, California and, as a result, $0.2 million of operating right-of-use assets related to the abandonment of the laboratory were written off to research and development expense during the nine months ended September 30, 2021. The components of lease cost for operating leases were as follows: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Operating leases Operating lease cost $ 107,969 $ 182,287 $ 383,672 $ 570,163 Variable lease cost 26,636 36,554 73,120 89,716 Operating lease expense 134,605 218,841 456,792 659,879 The table below summarizes other information related to the Company’s operating leases: Nine Months Ended September 30, 2021 2020 Cash paid for amounts included in measurement of operating lease liabilities $ 403,012 $ 665,095 Establishment of operating lease liabilities arising from obtaining right-of-use assets $ 1,302,457 $ 21,078 Weighted-average remaining lease term – operating leases 3.3 1.9 Weighted-average discount rate – operating leases 5.8 % 9.6 % Remaining maturities of the Company’s operating leases, excluding short-term leases, included in operating lease liabilities – non - current in the condensed consolidated balance sheets as of September 30, 2021 are as follows: 2021 $ 111,441 2022 481,549 2023 484,719 2024 484,631 2025 40,382 Total 1,602,722 Less present value discount (148,425 ) Total operating lease liabilities $ 1,454,297 Less operating lease liabilities - current (398,313 ) Operating lease liabilities - non-current $ 1,055,984 Financing Leases The Company has a number of computer and copier equipment leases that are classified as financing leases. Incremental borrowing rates used to discount future lease payments in calculating lease liabilities were estimated by reference to information received by the Company from bankers regarding estimated current borrowing rates for collateralized loans with similar amount and duration as the leases. The components of lease cost for financing leases were as follows: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Financing leases Amortization of right-of-use assets $ 5,444 $ 10,035 $ 18,501 $ 34,033 Interest on lease liability 1,369 2,092 4,544 7,074 Total financing lease cost $ 6,813 $ 12,127 $ 23,045 $ 41,107 The table below summarizes other information related to the Company’s financing leases: Nine Months Ended September 30, 2021 2020 Weighted-average remaining lease term – financing leases 3.0 3.5 Weighted-average discount rate – financing leases 9.77 % 9.77 % As of September 30, 2021, remaining maturities of the Company’s financing leases are as follows: 2021 $ 5,772 2022 20,715 2023 18,396 2024 16,080 Total 60,963 Less present value discount (8,328 ) Financing lease liabilities, net $ 52,635 Financing lease liabilities net of discount of $52,635, of which $17,558 and $35,077 were included in other current liabilities and other non-current liabilities, respectively, and financing right-of-use assets of $48,269, were included in property and equipment, net, in the condensed consolidated balance sheet as of September 30, 2021.

Net Loss per Share

Net Loss per Share	9 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
Net Loss per Share	Note 12. Net Loss Per Share Basic loss per common share is computed by dividing net loss allocable to common stockholders by the weighted average number of shares of common stock or common stock equivalents outstanding. Diluted loss per common share is computed similar to basic loss per The following common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because their effect would have been anti-dilutive: Nine Months Ended September 30, 2021 2020 Options to purchase common stock 494,250 499,033 Series A Preferred 158,545 — Common stock warrants 58,688 58,688 Unvested restricted stock units 6,301 13,603

Warrants

Warrants	9 Months Ended
	Sep. 30, 2021
Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants [Abstract]
Warrants	Note 13. Warrants In connection with certain of its redeemable convertible preferred stock issuances, convertible debt financings and other financing arrangements, the Company has issued warrants for shares of its common stock and various issues of its redeemable convertible preferred stock, which have since been converted to common stock warrants. In connection with the Securities Purchase Agreement (see Note 14), the Company issued and sold pre-funded warrants exercisable for an aggregate of 360,779 shares of common stock. The total exercise price of the pre-funded warrants is $9.75 per share, $9.60 of which was pre-funded and paid to the Company upon issuance of the pre-funded warrants. The remaining exercise price of the pre-funded warrants is $0.15 per share. In March 2020, 211,784 of the pre-funded warrants were exercised for proceeds of $31,768. In June 2021, the remaining 148,995 pre-funded warrants were exercised on a cashless, net exercise basis, resulting in the issuance of 144,881 shares of common stock. In connection with the SVB Term Loan (see Note 8), the Company granted to SVB a warrant to purchase up to 42,894 shares of the Company’s common stock at a purchase price of $11.6565 per share. The warrant will expire on June 24, 2030 and may be exercised for cash or at the election of the holder on a cashless, net exercise basis. The following table shows the common stock warrants outstanding as of September 30, 2021: Warrant Issuance Date Shares of Common Underlying Warrants Exercise Price/Share Expiration Date August 2014 1,914 $ 352.65 2024 December 2014 9,651 210.00 2022 March 2016 3,021 41.40 2026 March 2018 1,208 115.95 2028 June 2020 42,894 11.6565 2030

Stockholders Deficit

Stockholders Deficit	9 Months Ended
	Sep. 30, 2021
Equity [Abstract]
Stockholders' Deficit	Note 14. Stockholders’ Deficit Reverse Stock Split On November 20, 2020, the Company completed a reverse stock split of its outstanding shares of common stock pursuant to which every fifteen (15) Equity Offerings Securities Purchase Agreement In September 2019, concurrently with the closing of an underwritten public offering, the Company entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with certain institutional accredited investors (the “Purchasers”), pursuant to which the Company sold to the Purchasers, in a private placement transaction, warrants to purchase up to an aggregate of 360,779 shares of its common stock (“Warrant Shares”), at a price of $9.60 per warrant (which $9.60 price relates to the pre-funded portion of the total $9.75 exercise price per share). Each pre-funded warrant has a remaining exercise price of $0.15 per share and became immediately exercisable upon issuance, subject to certain beneficial ownership limitations. In March 2020, 211,784 of the pre-funded warrants were exercised for additional proceeds of $31,768. In June 2021, the remaining 148,995 pre-funded warrants were exercised on a cashless, net exercise basis, resulting in the issuance of 144,881 shares of the Company’s common stock. ATM Offering In November 2019, the Company entered into a Controlled Equity Offering Sales Agreement (the “Cantor Sales Agreement”) with Cantor as the sales agent, pursuant to which the Company may offer and sell, from time to time, through Cantor, shares of its common stock, par value $0.001 per share, by any method deemed to be an “at the market offering” as defined in Rule 415(a)(4) under the Securities Act (the “ATM Offering”). The shares are offered and sold pursuant to the Company’s shelf registration statement on Form S-3 (File No. 333-229045). During the nine months ended September 30, 2021, the Company sold 2,050,879 shares of common stock under the ATM Offering at then-market prices for total gross proceeds of approximately $11.0 million. After paying sales commissions owed in connection with the ATM Offering of approximately $0.3 million, the Company’s aggregate net proceeds for the nine months ended September 30, 2021 were approximately $10.7 million. Exchange and Private Placement On February 25, 2020, the Company entered into an Exchange and Purchase Agreement (the “Exchange Agreement”) with certain accredited investors (the “Investors”) pursuant to which the Company agreed to (i) issue to the Investors an aggregate of 41,100 shares of its newly designated Series A Convertible Preferred Stock, par value $0.001 per share (“Series A Preferred”), in exchange for the Investors surrendering to the Company for cancellation an aggregate of 274,000 shares of its common stock (the “Exchange”) and (ii) sell and issue to the Investors an aggregate of 10,170 shares of Series A Preferred for an aggregate purchase price of $0.6 million, or $59.00 per share (the “Private Placement”). The common stock acquired in the Exchange was immediately retired. Each share of Series A Preferred is convertible into 6.67 shares of the Company’s common stock, subject to proportional adjustment and beneficial ownership limitations. In June 2020, certain of the Investors elected to convert 27,500 shares of Series A Preferred to common stock in the aggregate, resulting in the issuance of 183,333 shares of the Company’s common stock. The remaining 23,770 Series A Preferred shares remain outstanding as of September 30, 2021. In the event of the Company’s liquidation, dissolution or winding up, holders of Series A Preferred will participate pari passu with any distribution of proceeds to holders of the Company’s common stock. Holders of Series A Preferred are entitled to receive dividends on shares of Series A Preferred equal (on an as converted to common stock basis) to and in the same form as dividends actually paid on the Company’s common stock. Shares of Series A Preferred generally have no voting rights, except as required by law. LP Purchase Agreement On March 24, 2020, the Company entered into a purchase agreement (“LP Purchase Agreement”) with Lincoln Park Capital Fund, LLC (“Lincoln Park”), pursuant to which, upon the terms and subject to the conditions and limitations set forth therein, the Company has the right to sell to Lincoln Park up to $20.0 million of shares of its common stock (“Purchase Shares”) from time to time over the 36-month term of the LP Purchase Agreement. The purchase price of the Purchase Shares is established by a formula based on the recent closing prices of the Company’s common stock leading up to the date of sale. The Company issued Lincoln Park an aggregate of 41,026 shares of its common stock as consideration for their purchase commitment pursuant to the LP Purchase Agreement. The Company did not receive cash proceeds from the issuance of such shares. The value of this commitment consideration, as well as related transaction costs of approximately $0.1 million was included in s elling, general and administrative expense in the accompanying condensed consolidated statements of operations during the year ended December 31, 2020 During the nine months ended September 30, 2021, the Company sold Stock-based Compensation The Company incurs stock-based compensation expense relating to the grants of RSUs and stock options to employees, non-employee directors and consultants under its equity incentive plans and through stock purchase rights granted under the employee stock purchase plan. Stock-based compensation expense (including employee stock purchase plan expense) recorded in the accompanying condensed consolidated statements of operations for the three and nine months ended September 30, 2021 and 2020 was as follows: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Selling, general and administrative $ 293,916 $ 383,679 $ 934,446 $ 1,079,754 Research and development 35,566 2,044 83,108 85,462 Cost of product and product-related services revenue 9,411 6,440 24,764 14,498 $ 338,893 $ 392,163 $ 1,042,318 $ 1,179,714 Equity Compensation Plans In August 2020, the Company’s stockholders, upon the recommendation of the Company’s Board of Directors, approved the 2020 Equity Incentive Plan (the “2020 Plan”) as a successor to and continuation of the 2014 Plan. Upon approval of the 2020 Plan, 744,685 shares of the Company’s common stock, including 68,552 remaining shares reserved for issuance under the 2014 Plan (excluding shares available for the granting of inducement awards under the 2014 Plan’s inducement share pool), were reserved for issuance under the 2020 Plan. No new awards, including inducement awards, may be granted under the 2014 Plan. The 2020 Plan does not contain an evergreen provision. There were 538,959 shares of the Company’s common stock available for issuance under the 2020 Plan (excluding shares available for granting of inducement awards under the 2021 Inducement Plan) as of September 30, 2021, in addition to shares that may become available from time to time as shares of the Company’s common stock subject to outstanding awards granted under the 2014 Plan (excluding inducement awards issued from the 2014 Plan’s inducement share pool), the 2011 Equity Incentive Plan or the 2001 Stock Option Plan (i) are not issued because such award or any portion thereof expires or otherwise terminates without all of the shares covered by such award having been issued; (ii) are not issued because such award or any portion thereof is settled in cash; or (iii) are forfeited back to or repurchased by the Company because of the failure to meet a contingency or condition required for the vesting of such shares. In August 2021, the Company’s stockholders, upon the recommendation of the Company’s Board of Directors, approved the Amended and Restated 2014 Employee Stock Purchase Plan (the “Amended 2014 ESPP”). Upon approval of the Amended 2014 ESPP, 500,000 shares of the Company’s common stock were reserved for issuance under the Amended 2014 ESPP in addition to 24,285 shares of the Company’s common stock reserved for issuance under the original 2014 Employee Stock Purchase Plan. The Amended 2014 ESPP does not contain an evergreen provision. In July 2021, the Company’s Board of Directors adopted the Company’s 2021 Inducement Plan (the “2021 Inducement Plan”), pursuant to which 300,000 shares were initially authorized and reserved for issuance exclusively for the grant of awards to individuals who were not previously employees or non-employee directors of the Company, as inducement material to the individuals’ entering into employment with the Company (“Inducement Awards”). There were 270,000 shares of the Company’s stock available for issuance under the 2021 Inducement Plan as of September 30, 2021, in addition to shares that may become available from time to time as shares of the Company’s common stock subject to outstanding awards granted under the 2021 Inducement Plan are forfeited back to or repurchased by the Company because of the failure to meet a contingency or condition required for the vesting of such shares. A summary of the Company’s stock option activity for the nine months ended September 30, 2021 is as follows: Number of Shares Weighted- Average Exercise Price Per Share Weighted- Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Balance at December 31, 2020 487,227 $ 16.78 8.6 $ 1,536 Granted 70,333 5.74 Exercised (75 ) 4.35 $ 107 Forfeited (45,006 ) 12.76 Expired/Cancelled (18,229 ) 25.64 Balance at September 30, 2021 494,250 $ 15.25 8.2 $ 19,222 Exercisable at September 30, 2021 283,107 $ 20.65 7.6 $ 5,882 Stock option activity includes 30,000 Inducement Awards granted during the three and nine months ended September 30, 2021. As of September 30, 2021, total unrecognized compensation cost related stock option awards was approximately $1.3 million, which is expected to be recognized over approximately 2.18 years. The following table summarizes restricted stock unit (“RSU”) award activity for the nine months ended September 30, 2021: Number of Shares Weighted- Average Grant Date Fair Value Per Share Balance at December 31, 2020 12,214 $ 28.61 Released (3,540 ) 29.96 Forfeited (2,373 ) 51.00 Balance at September 30, 2021 6,301 $ 19.40 Vested and unissued at September 30, 2021 989 $ 26.14 Vested and unissued awards at September 30, 2021 represents RSU awards for which the vesting date was September 30, 2021, but for which issuance of the awards occurred in October 2021

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2021
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 15. Commitments and Contingencies Legal Matters The Company’s industry is characterized by frequent claims and litigation, including claims regarding intellectual property and product liability. As a result, the Company may be subject to various legal proceedings from time to time. The results of any current or future litigation cannot be predicted with certainty, and regardless of the outcome, litigation can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources and other factors. Any current litigation is considered immaterial and counter claims have been assessed as remote. Product Warranty The following is a summary of the Company’s general product warranty liability. Product warranty liabilities of approximately $93,000 and $27,000 were included in accrued liabilities and other non-current liabilities, respectively, in the accompanying condensed consolidated balance sheets as of September 30, 2021. Expense relating to the recording of this reserve is recorded in cost of product and product-related services revenue within the accompanying condensed consolidated statements of operations. Nine Months Ended September 30, 2021 2020 Beginning balance $ 92,696 $ 94,482 Cost of warranty claims (141,648 ) (19,310 ) Increase in warranty reserve 169,337 12,423 Ending balance $ 120,385 $ 87,595

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
COVID-19 Pandemic	COVID-19 Pandemic The full impact of the COVID-19 pandemic (“COVID-19”) continues to evolve as of the date of this report and management continues to actively monitor the potential impact of the global situation on its financial condition, liquidity and future results of operations, suppliers, industry and workforce. Given the ongoing evolution of COVID-19, including the emergence of variants and resurgences in many areas of the world and the global responses to curb its spread, the Company is not able to fully estimate the effects of COVID-19 on its results of operations, financial condition or liquidity. The Company experienced a significant slowing of product and product-related services revenue generation beginning in March 2020 and continuing throughout 2020 and the three quarters of 2021. The extent of this impact has varied from customer to customer depending upon how they have been directly or indirectly impacted by local stay-at-home orders and other social distancing measures, prioritization by those customers as the immediate impacts of the pandemic have passed, and the workforce and supplier impacts that COVID-19 has had on each customer. In March 2020, the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) was enacted in response to COVID-19. On April 21, 2020, the Company received proceeds from a loan pursuant to the Paycheck Protection Program (“PPP”) of the CARES Act (the “PPP Loan”) in the amount of $1.7 million from Silicon Valley Bank (“SVB”), as lender (see Note 8). The Company applied for full forgiveness of the PPP Loan in October 2020. In May 2021, the Company received notification that the PPP Loan and related accrued interest, totaling $1,735,792, were forgiven by the U.S. Small Business Administration (“SBA”), and that the PPP Loan note had been canceled. In December 2020, the Consolidated Appropriations Act (the “Appropriations Act”) was signed into law to further address the ongoing impacts of COVID-19. The Appropriations Act introduced several additional potential credits and benefits for employers to consider applying for, including, but not limited to, the ability for employers who have previously obtained a PPP Loan to potentially also qualify for Employee Retention Credits (“ERC”), initially created as part of the CARES Act. In March 2021, the American Rescue Plan of 2021 was enacted to, amongst other things, extend and expand ERC benefits through December 31, 2021. The Company has qualified for certain ERC benefits during the year ended December 31, 2020 and the first three quarters of 2021 and expects to continue to seek out these benefits in future periods as appropriate. ERC benefits of approximately $0.6 million and $1.7 million were included in operating expenses as an offset to the related compensation costs in the accompanying condensed consolidated statements of operations for the three and nine months ended September 30, 2021, respectively. While there remains uncertainty as to the ultimate impact of COVID-19, the Company has considered the known impacts on its business as of the date these condensed consolidated financial statements were issued and has reflected any known or expected impacts in its condensed consolidated financial statements, including consideration of potential impairment risks to its long-lived assets, potential accounts receivable collection risks and potential impacts to its overall liquidity position.
Basis of Presentation	Basis of Presentation The accompanying condensed consolidated financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and reflect the accounts of the Company as of September 30, 2021 and for the three and nine months ended September 30, 2021 and 2020. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America (“GAAP”) for complete financial statements. The accompanying condensed consolidated financial statements reflect all normal recurring adjustments which, in the opinion of management, are necessary for a fair statement of the Company’s financial position and the results of its operations and cash flows, as of and for the periods presented. The accompanying condensed consolidated balance sheet at December 31, 2020 has been derived from the audited consolidated financial statements at that date but does not include all of the information and disclosures required by GAAP for annual financial statements. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the full year. These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto for the year ended December 31, 2020, included in the Company’s Annual Report on Form 10-K filed with the SEC on March 25, 2021.
Going Concern and Liquidity	Going Concern and Management has assessed the Company’s ability to continue as a going concern within one year of issuance of these financial statements. The accompanying interim unaudited condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of the assets and satisfaction of liabilities in the normal course of business. However, the Company has had recurring operating losses and negative operating cash flows since its inception and has an accumulated deficit of $203.1 million as of September 30, 2021. As of September 30, 2021, the Company had working capital of $23.7 million and long-term liabilities of $11.5 million. The Company’s liability balances consist primarily of its debt obligations, including an asset-secured loan with Silicon Valley Bank (the “SVB Term Loan”), as well as an obligation to NuvoGen Research, LLC (the “NuvoGen obligation”) (see Note 10). Potentially changing circumstances, including COVID-19 uncertainties, may result in the depletion of the Company’s capital resources more rapidly than it currently anticipates, resulting in the Company not having adequate resources to fund its planned operations and expenditures for at least the next 12 months and to comply with the financial covenant in the Loan and Security Agreement for the SVB Term Loan (the “Loan Agreement”). These circumstances raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying condensed consolidated financial statements do not include any adjustments that may result from the outcome of these uncertainties. The Company will need to raise additional capital to fund its operations and service its long-term debt obligations until its revenue reaches a level sufficient to provide for self-sustaining cash flows. There can be no assurance that additional capital will be available on acceptable terms, or at all, or that the Company’s revenue will reach a level sufficient to provide for self-sustaining cash flows. In addition, the Company must comply with a financial covenant in the SVB Term Loan requiring the Company to maintain unrestricted cash of not less than the greater of (i) $12.5 million and (ii) an amount equal to six times the amount of the Company’s average monthly Cash Burn (as defined in the Loan Agreement) over the trailing three months.
Principles of Consolidation	Principles of Consolidation The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, HTG Molecular Diagnostics France, SARL, after elimination of all intercompany transactions and balances as of September 30, 2021 and December 31, 2020.
Concentration Risks	Concentration Risks Financial instruments that potentially subject the Company to credit risk consist principally of cash and cash equivalents and accounts receivable. The Company maintains the majority of its cash balances in the form of cash deposits in bank checking and money market accounts in amounts in excess of federally insured limits. Management believes, based upon the quality of the financial institution, that the credit risk with regard to these deposits is not significant. The Company sells its instrument, related consumables, sample processing services, custom RUO assay design and collaborative development services primarily to biopharmaceutical companies, academic institutions and molecular labs. The Company routinely assesses the financial strength of its customers and credit losses have been minimal to date. The Company’s top two customers accounted for 27% and 13% of the Company’s total revenue for the three months ended September 30, 2021, compared with the Company’s top two customers accounting for 24% and 10% of the Company’s total revenue for the three months ended September 30, 2020. The Company’s top two customers accounted for 23% and 12% of the Company’s total revenue for the nine months ended September 30, 2021, compared with the Company’s top two customer accounting for 16% and 10% of the Company’s total revenue for the nine months ended September 30, 2020. The largest two customers accounted for 52% and 11% of the Company’s accounts receivable as of September 30, 2021. The largest two customers accounted for approximately 9% each of the Company’s accounts receivable as of December 31, 2020. Three vendors accounted for 26%, 14% and 10% of the Company’s accounts payable as of September 30, 2021, compared with two vendors who accounted for 21% and 20% of the Company’s accounts payable as of December 31, 2020. The Company currently relies on a single supplier to produce a subcomponent used in its HTG EdgeSeq processors. A loss of this supplier could significantly delay the delivery of processors, which in turn could materially affect the Company’s ability to generate revenue.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The Company’s estimates include revenue recognition, stock-based compensation expense, bonus and warranty accrual, income tax valuation allowances and reserves, recovery of long‑lived assets, lease liability, inventory obsolescence and valuation of inventory, accounts receivable and available-for-sale securities. Actual results could materially differ from those estimates, especially in light of the significant uncertainty that remains as to the full impact of COVID-19 on the Company’s operations, as well as those of its workforce, supply chains, distribution networks and those of its customers.
Significant Accounting Policies	Significant Accounting Policies There have been no material changes in the Company’s significant accounting policies from those previously disclosed in the consolidated financial statements included in the Company’s Annual Report on Form 10-K, filed with the SEC on March 25, 2021.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The carrying value of financial instruments classified as current assets and current liabilities approximate fair value due to their liquidity and short-term nature. Investments that are classified as available-for-sale are recorded at fair value, which is determined using quoted market prices, broker or dealer quotations or alternative pricing sources with reasonable levels of price transparency. The carrying value of the SVB Term Loan (see Note 8) is estimated to approximate its fair value as the interest rate approximates the market rate for debt with similar terms and risk characteristics. The NuvoGen obligation relates to an asset purchase transaction with a then-common stockholder of the Company (see Note 10). As of September 30, 2021, the estimated aggregate fair value of the NuvoGen obligation is approximately $4.7 million, determined using a Monte Carlo simulation with key assumptions including future revenue, volatility, discount and risk-free rates.
Recently Adopted and New Accounting Pronouncements	Recently Adopted Accounting Pronouncements In October 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Codification (“ASC” or the “FASB Codification”) Update (“ASU”) No. 2020-10, Codification Improvements (“Update No. 2020-10”), which amended a variety of topics in the FASB Codification in order to improve the consistency of the Codification and the application thereof, while leaving GAAP unchanged. Update No. 2020-10 was effective for fiscal years beginning after December 15, 2020 for public business entities. The Company’s adoption of this standard on January 1, 2021 did not have a material impact on its condensed consolidated financial statements or related footnote disclosures. In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes New Accounting Pronouncements The following are new FASB ASUs that had not been adopted by the Company as of September 30, 2021: In August 2020, the FASB issued ASU No. 2020-06, Debt – Debt with Conversion and other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and also simplifies the diluted earnings per share calculation in certain areas. The standard is effective for public business entities, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years and interim periods within those fiscal years, beginning after December 15, 2021. For all other entities, the standard will be effective for fiscal years beginning after December 15, 2023. Early adoption is permitted, and adoption must be as of the beginning of the Company’s annual fiscal year. The Company is currently evaluating the impact of this standard on its consolidated financial statements and related disclosures. In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses

Inventory (Tables)

Inventory (Tables)	9 Months Ended
	Sep. 30, 2021
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventory, net of allowance, consisted of the following as of the dates indicated: September 30, December 31, 2021 2020 Raw materials $ 1,662,205 $ 1,079,528 Work in process 235,637 147,455 Finished goods 459,317 291,195 Total gross inventory 2,357,159 1,518,178 Less inventory allowance (16,393 ) (26,052 ) $ 2,340,766 $ 1,492,126

Fair Value Instruments (Tables)

Fair Value Instruments (Tables)	9 Months Ended
	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Financial Assets and Liabilities Measured at Fair Value on Recurring Basis	The following table classifies the Company’s financial assets and liabilities measured at fair value on a recurring basis as of September 30, 2021 and December 31, 2020 in the fair value hierarchy: September 30, 2021 Level 1 Level 2 Level 3 Total Asset included in: Cash and cash equivalents Money market securities $ 10,055,376 $ — $ — $ 10,055,376 Investments available-for-sale at fair value Corporate debt securities — 15,187,672 — 15,187,672 Total $ 10,055,376 $ 15,187,672 $ — $ 25,243,048 December 31, 2020 Level 1 Level 2 Level 3 Total Asset included in: Cash and cash equivalents Money market securities $ 17,497,282 $ — $ — $ 17,497,282 Corporate debt securities — 4,499,270 — 4,499,270 Investments available-for-sale at fair value Corporate debt securities — 6,298,075 — 6,298,075 Total $ 17,497,282 $ 10,797,345 $ — $ 28,294,627

Available-for-Sale Securities (

Available-for-Sale Securities (Tables)	9 Months Ended
	Sep. 30, 2021
Investments Debt And Equity Securities [Abstract]
Summary of Available-for-sale Securities	The Company’s portfolio of available-for-sale securities consists of high credit quality corporate debt securities. The following is a summary of the Company’s available-for-sale securities as of September 30, 2021 and December 31, 2020: September 30, 2021 Gross Gross Fair Value Amortized Unrealized Unrealized (Net Carrying Cost Gains Losses Amount) Corporate debt securities 15,187,672 — — 15,187,672 Total available-for-sale securities $ 15,187,672 $ — $ — $ 15,187,672 December 31, 2020 Gross Gross Fair Value Amortized Unrealized Unrealized (Net Carrying Cost Gains Losses Amount) Corporate debt securities 6,298,075 — — 6,298,075 Total available-for-sale securities $ 6,298,075 $ — $ — $ 6,298,075
Summary of Contractual Maturities of Debt Investment Securities	Contractual maturities of debt investment securities as of September 30, 2021 are shown below. Under 1 Year 1 to 2 Years Total Corporate debt securities 15,187,672 — 15,187,672 Total available-for-sale securities $ 15,187,672 $ — $ 15,187,672

Property and Equipment (Tables)

Property and Equipment (Tables)	9 Months Ended
	Sep. 30, 2021
Property Plant And Equipment [Abstract]
Summary of Property and Equipment	Property and equipment, net, consists of the following as of the dates indicated: September 30, December 31, 2021 2020 Furniture & fixtures $ 1,086,341 $ 1,082,717 Leasehold improvements 1,931,762 1,943,534 Equipment used in manufacturing 2,673,452 2,166,743 Equipment used in research & development 2,506,644 2,506,644 Equipment used in the field 182,762 208,005 Software 488,098 420,301 Property and equipment 8,869,059 8,327,944 Less: accumulated depreciation and amortization (7,649,869 ) (7,100,542 ) $ 1,219,190 $ 1,227,402

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	9 Months Ended
	Sep. 30, 2021
Accrued Liabilities Current [Abstract]
Summary of Accrued Liabilities	Accrued liabilities consisted of the following as of the dates indicated: September 30, December 31, 2021 2020 Accrued employee bonuses $ 775,219 $ 436,799 Payroll and employee benefit accruals 414,177 694,058 Accrued product warranty 92,696 92,696 Other accrued liabilities 326,909 236,325 $ 1,609,001 $ 1,459,878

Debt Obligations (Tables)

Debt Obligations (Tables)	9 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
Schedule of Current Portion of Long-term Debt, Net	Current portion of long-term debt consisted of the following as of the dates indicated: September 30, December 31, 2021 2020 SVB Term Loan $ 3,750,000 $ 2,000,000 PPP Loan — 857,040 2021 Insurance Note 417,107 — 2020 Insurance Note — 165,099 $ 4,167,107 $ 3,022,139
Schedule of Long Term Debt, Net of Current Portion and Discount and Debt Issuance Costs	Long-term debt, net of current portion, discount and debt issuance costs, consisted of the following as of the dates indicated: September 30, December 31, 2021 2020 SVB Term Loan, net of discount and debt issuance costs $ 6,309,416 $ 7,708,348 PPP Loan — 859,960 $ 6,309,416 $ 8,568,308
Schedule of Remaining Principal Repayments due Under SVB Term Loan	The remaining principal repayments due under the SVB Term Loan as of September 30, 2021 are as follows for each fiscal year: 2021 $ - 2022 5,000,000 2023 5,000,000 Total SVB Term Loan payments 10,000,000 Less discount and deferred financing costs (740,584 ) Plus final fee premium 800,000 Total SVB Term Loan, net $ 10,059,416

Revenue from Contracts with C_2

Revenue from Contracts with Customers (Tables)	9 Months Ended
	Sep. 30, 2021
Revenue From Contract With Customer [Abstract]
Product and Product-Related Service Revenue from Sale of Instruments and Consumables	Product and Product-related Services Revenue The Company had product and product-related services revenue consisting of revenue from the sale of instruments and consumables and the use of the HTG EdgeSeq proprietary technology to process samples and design custom RUO assays for the three and nine months ended September 30, 2021 and 2020 as follows: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Product revenue: Instruments $ 407,130 $ 71,742 $ 1,028,348 $ 563,396 Consumables 793,542 764,605 2,265,894 2,091,848 Total product revenue 1,200,672 836,347 3,294,242 2,655,244 Product-related services revenue: Custom RUO assay design — 238,502 48,350 1,210,968 RUO sample processing 1,319,738 626,219 2,687,168 1,551,519 Total product-related services revenue 1,319,738 864,721 2,735,518 2,762,487 Total product and product-related services revenue $ 2,520,410 $ 1,701,068 $ 6,029,760 $ 5,417,731
Schedule of Collaborative Development Services	The Company enters into collaborative development services agreements with biopharmaceutical companies for the development of NGS-based companion diagnostic assays in support of and in conjunction with, biopharmaceutical companies’ drug development programs. These collaborative development services agreements may generate upfront fees, and in some cases subsequent milestone payments that may be earned upon completion of certain product development milestones or activities. The Company follows ASC 606 and ASC 808 to determine the appropriate recognition of revenue under its collaborative research, development and commercialization agreements. Because each SOW had an expected duration of one year or less, the Company elected the practical expedient in ASC 606-10-50-14(a) not to disclose information about its remaining performance obligations for each SOW. Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Collaborative development services $ — $ 76,030 $ — $ 548,135
Schedule of Changes in Contract Liability	Changes in the Company’s contract liability were as follows as of the dates indicated: Product Revenue Custom RUO Assay Design Sample Processing Total Contract Liability Balance at January 1, 2021 $ 103,580 $ - $ 93,884 $ 197,464 Deferral of revenue 261,100 — 525,899 786,999 Recognition of deferred revenue (198,438 ) — (535,501 ) (733,939 ) Balance at September 30, 2021 $ 166,242 $ — $ 84,282 $ 250,524 Product Revenue Custom RUO Assay Design Sample Processing Total Contract Liability Balance at January 1, 2020 $ 95,148 $ 66,216 $ 438,090 $ 599,454 Deferral of revenue 335,265 459,385 77,104 871,754 Recognition of deferred revenue (325,181 ) (525,601 ) (95,670 ) (946,452 ) Balance at September 30, 2020 $ 105,232 $ — $ 419,524 $ 524,756

Other Agreements (Tables)

Other Agreements (Tables)	9 Months Ended
	Sep. 30, 2021
Other Agreements [Abstract]
Schedule of Remaining Minimum Principal Payments Due	The remaining minimum payments to be made to NuvoGen as of September 30, 2021 are as follows for each fiscal year: 2021 $ 151,225 2022 479,432 2023 400,000 2024 400,000 2025 400,000 2026 and beyond 2,702,661 Total NuvoGen obligation payments 4,533,318 Plus interest accretion 70,170 Total NuvoGen obligation, net $ 4,603,488

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2021
Leases [Abstract]
Summary of Components of Lease Cost	The components of lease cost for operating leases were as follows: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Operating leases Operating lease cost $ 107,969 $ 182,287 $ 383,672 $ 570,163 Variable lease cost 26,636 36,554 73,120 89,716 Operating lease expense 134,605 218,841 456,792 659,879 The components of lease cost for financing leases were as follows: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Financing leases Amortization of right-of-use assets $ 5,444 $ 10,035 $ 18,501 $ 34,033 Interest on lease liability 1,369 2,092 4,544 7,074 Total financing lease cost $ 6,813 $ 12,127 $ 23,045 $ 41,107
Summary of Other Information Related to Operating Leases	The table below summarizes other information related to the Company’s operating leases: Nine Months Ended September 30, 2021 2020 Cash paid for amounts included in measurement of operating lease liabilities $ 403,012 $ 665,095 Establishment of operating lease liabilities arising from obtaining right-of-use assets $ 1,302,457 $ 21,078 Weighted-average remaining lease term – operating leases 3.3 1.9 Weighted-average discount rate – operating leases 5.8 % 9.6 %
Summary of Remaining Maturities of Operating Leases, Excluding Short-term Leases	Remaining maturities of the Company’s operating leases, excluding short-term leases, included in operating lease liabilities – non - current in the condensed consolidated balance sheets as of September 30, 2021 are as follows: 2021 $ 111,441 2022 481,549 2023 484,719 2024 484,631 2025 40,382 Total 1,602,722 Less present value discount (148,425 ) Total operating lease liabilities $ 1,454,297 Less operating lease liabilities - current (398,313 ) Operating lease liabilities - non-current $ 1,055,984
Summary of Other Information Related to Financing Leases	The table below summarizes other information related to the Company’s financing leases: Nine Months Ended September 30, 2021 2020 Weighted-average remaining lease term – financing leases 3.0 3.5 Weighted-average discount rate – financing leases 9.77 % 9.77 %
Summary of Remaining Maturities of Financing Leases	As of September 30, 2021, remaining maturities of the Company’s financing leases are as follows: 2021 $ 5,772 2022 20,715 2023 18,396 2024 16,080 Total 60,963 Less present value discount (8,328 ) Financing lease liabilities, net $ 52,635

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
Common Stock Equivalents Excluded from Computation of Diluted Net Loss per Share	The following common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because their effect would have been anti-dilutive: Nine Months Ended September 30, 2021 2020 Options to purchase common stock 494,250 499,033 Series A Preferred 158,545 — Common stock warrants 58,688 58,688 Unvested restricted stock units 6,301 13,603

Warrants (Tables)

Warrants (Tables)	9 Months Ended
	Sep. 30, 2021
Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants [Abstract]
Summary of Outstanding Warrants	The following table shows the common stock warrants outstanding as of September 30, 2021: Warrant Issuance Date Shares of Common Underlying Warrants Exercise Price/Share Expiration Date August 2014 1,914 $ 352.65 2024 December 2014 9,651 210.00 2022 March 2016 3,021 41.40 2026 March 2018 1,208 115.95 2028 June 2020 42,894 11.6565 2030

Stockholders Deficit (Tables)

Stockholders Deficit (Tables)	9 Months Ended
	Sep. 30, 2021
Equity [Abstract]
Summary of Stock Based Compensation Recognized in Consolidated Statement of Operations	Stock-based compensation expense (including employee stock purchase plan expense) recorded in the accompanying condensed consolidated statements of operations for the three and nine months ended September 30, 2021 and 2020 was as follows: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Selling, general and administrative $ 293,916 $ 383,679 $ 934,446 $ 1,079,754 Research and development 35,566 2,044 83,108 85,462 Cost of product and product-related services revenue 9,411 6,440 24,764 14,498 $ 338,893 $ 392,163 $ 1,042,318 $ 1,179,714
Summary of Stock Option Plans Activity	A summary of the Company’s stock option activity for the nine months ended September 30, 2021 is as follows: Number of Shares Weighted- Average Exercise Price Per Share Weighted- Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Balance at December 31, 2020 487,227 $ 16.78 8.6 $ 1,536 Granted 70,333 5.74 Exercised (75 ) 4.35 $ 107 Forfeited (45,006 ) 12.76 Expired/Cancelled (18,229 ) 25.64 Balance at September 30, 2021 494,250 $ 15.25 8.2 $ 19,222 Exercisable at September 30, 2021 283,107 $ 20.65 7.6 $ 5,882
Summary of Restricted Stock Unit ("RSU") Award Activity	The following table summarizes restricted stock unit (“RSU”) award activity for the nine months ended September 30, 2021: Number of Shares Weighted- Average Grant Date Fair Value Per Share Balance at December 31, 2020 12,214 $ 28.61 Released (3,540 ) 29.96 Forfeited (2,373 ) 51.00 Balance at September 30, 2021 6,301 $ 19.40 Vested and unissued at September 30, 2021 989 $ 26.14

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2021
Commitments And Contingencies Disclosure [Abstract]
Summary of Product Warranty Liability	The following is a summary of the Company’s general product warranty liability Nine Months Ended September 30, 2021 2020 Beginning balance $ 92,696 $ 94,482 Cost of warranty claims (141,648 ) (19,310 ) Increase in warranty reserve 169,337 12,423 Ending balance $ 120,385 $ 87,595

Description of Business, Basi_2

Description of Business, Basis of Presentation and Principles of Consolidation - Additional Information (Details)	Apr. 21, 2020USD ($)	May 31, 2021USD ($)	Sep. 30, 2021USD ($)Customer	Sep. 30, 2020Customer	Sep. 30, 2021USD ($)SegmentCustomer	Sep. 30, 2020USD ($)Customer	Dec. 31, 2020USD ($)Customer
Significant Accounting Policies [Line Items]
Number of operating segments | Segment					1
Proceeds from PPP Loan						$ 1,717,000
Gain on forgiveness of PPP Loan					$ 1,735,792
Employee retention credit benefits			$ 600,000		1,700,000
Accumulated deficit			(203,141,742)		(203,141,742)		$ (191,187,861)
Working capital			23,700,000		23,700,000
Long-term liabilities			11,500,000		11,500,000
Debt instrument, covenant unrestricted cash			$ 12,500,000		$ 12,500,000
U.S. Small Business Administration
Significant Accounting Policies [Line Items]
Gain on forgiveness of PPP Loan		$ 1,735,792
Paycheck Protection Program Loan | Silicon Valley Bank
Significant Accounting Policies [Line Items]
Proceeds from PPP Loan	$ 1,700,000
Sales Revenue, Net | Customer Concentration Risk
Significant Accounting Policies [Line Items]
Number of customers | Customer			2	2	2	2
Sales Revenue, Net | Customer Concentration Risk | Customers Located Outside Of United States
Significant Accounting Policies [Line Items]
Sales revenue percentage			24.00%	19.00%	30.00%	31.00%
Sales Revenue, Net | Customer Concentration Risk | Customer One
Significant Accounting Policies [Line Items]
Sales revenue percentage			27.00%	24.00%	23.00%	16.00%
Sales Revenue, Net | Customer Concentration Risk | Customer Two
Significant Accounting Policies [Line Items]
Sales revenue percentage			13.00%	10.00%	12.00%	10.00%
Accounts Payable | Customer Concentration Risk
Significant Accounting Policies [Line Items]
Number of customers | Customer					3		2
Accounts Payable | Customer Concentration Risk | Customer One
Significant Accounting Policies [Line Items]
Sales revenue percentage					26.00%		21.00%
Accounts Payable | Customer Concentration Risk | Customer Two
Significant Accounting Policies [Line Items]
Sales revenue percentage					14.00%		20.00%
Accounts Payable | Customer Concentration Risk | Customer Three
Significant Accounting Policies [Line Items]
Sales revenue percentage					10.00%
Accounts Receivable | Customer Concentration Risk
Significant Accounting Policies [Line Items]
Number of customers | Customer					2		2
Accounts Receivable | Customer Concentration Risk | Customer One
Significant Accounting Policies [Line Items]
Sales revenue percentage					52.00%		9.00%
Accounts Receivable | Customer Concentration Risk | Customer Two
Significant Accounting Policies [Line Items]
Sales revenue percentage					11.00%		9.00%

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Additional Information (Details) $ in Millions	Sep. 30, 2021USD ($)
ASU 2020-10
Significant Accounting Policies [Line Items]
Change in accounting principle, accounting standards update, adopted	true
Change in accounting principle, accounting standards update, adoption date	Jan. 1, 2021
Change in accounting principle, accounting standards update, immaterial effect	true
ASU 2019-12
Significant Accounting Policies [Line Items]
Change in accounting principle, accounting standards update, adopted	true
Change in accounting principle, accounting standards update, adoption date	Jan. 1, 2021
Change in accounting principle, accounting standards update, immaterial effect	true
NuvoGen Asset Purchase Agreement
Significant Accounting Policies [Line Items]
Convertible debt, fair value	$ 4.7

Inventory - Schedule of Invento

Inventory - Schedule of Inventory (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Inventory Disclosure [Abstract]
Raw materials	$ 1,662,205	$ 1,079,528
Work in process	235,637	147,455
Finished goods	459,317	291,195
Total gross inventory	2,357,159	1,518,178
Less inventory allowance	(16,393)	(26,052)
Inventory, net	$ 2,340,766	$ 1,492,126

Inventory - Additional Informat

Inventory - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Inventory [Line Items]
Provision for excess inventory	$ 54,636	$ 10,530	$ 60,143	$ 12,202
Finished goods inventory	459,317		459,317		$ 291,195
HTG EdgeSeq
Inventory [Line Items]
Finished goods inventory	$ 169,042		$ 169,042		$ 50,855

Fair Value Instruments - Financ

Fair Value Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Asset included in:
Investments available-for-sale at fair value	$ 15,187,672	$ 6,298,075
Corporate Debt Securities
Asset included in:
Investments available-for-sale at fair value	15,187,672	6,298,075
Fair Value, Measurements, Recurring
Asset included in:
Financial Assets	25,243,048	28,294,627
Fair Value, Measurements, Recurring | Money Market Securities
Asset included in:
Cash and cash equivalents	10,055,376	17,497,282
Fair Value, Measurements, Recurring | Corporate Debt Securities
Asset included in:
Cash and cash equivalents		4,499,270
Investments available-for-sale at fair value	15,187,672	6,298,075
Fair Value, Measurements, Recurring | Level 1
Asset included in:
Financial Assets	10,055,376	17,497,282
Fair Value, Measurements, Recurring | Level 1 | Money Market Securities
Asset included in:
Cash and cash equivalents	10,055,376	17,497,282
Fair Value, Measurements, Recurring | Level 2
Asset included in:
Financial Assets	15,187,672	10,797,345
Fair Value, Measurements, Recurring | Level 2 | Corporate Debt Securities
Asset included in:
Cash and cash equivalents		4,499,270
Investments available-for-sale at fair value	$ 15,187,672	$ 6,298,075

Fair Value Instruments - Additi

Fair Value Instruments - Additional Information (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Fair Value Disclosures [Abstract]
Fair value assets, Level 1 to Level 2 transfers, Amount	$ 0	$ 0
Fair value, assets, Level 2 to Level 1 transfers, Amount	0	0
Fair value, liabilities, Level 1 to Level 2 transfers, Amount	0	0
Fair value, liabilities, Level 2 to Level 1 transfers, Amount	0	0
Fair value, measurement with unobservable inputs reconciliation, recurring basis, asset transfers into Level 3	0	0
Fair value, measurement with unobservable inputs reconciliation, recurring Basis, asset, transfers out of Level 3	0	0
Fair Value, measurement with unobservable inputs reconciliation, liability, transfers into Level 3	0	0
Fair Value, measurement with unobservable inputs reconciliation, liability, transfers out of Level 3	$ 0	$ 0

Available-for-Sale Securities -

Available-for-Sale Securities - Summary of Available-for-sale Securities (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	$ 15,187,672	$ 6,298,075
Gross Unrealized Losses	0
Fair Value (Net Carrying Amount)	15,187,672	6,298,075
Corporate Debt Securities
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	15,187,672	6,298,075
Fair Value (Net Carrying Amount)	$ 15,187,672	$ 6,298,075

Available-for-Sale Securities_2

Available-for-Sale Securities - Additional Information (Details) - USD ($)	3 Months Ended				9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2021	Sep. 30, 2020
Investments Debt And Equity Securities [Abstract]
Available-for-sale securities investments, gross unrealized losses	$ 0				$ 0
Unrealized gain (loss) on short-term investments	$ 0	$ (17,501)	$ (26,136)	$ 47,697	$ 0	$ 4,060

Available-for-Sale Securities_3

Available-for-Sale Securities - Summary of Contractual Maturities of Debt Investment Securities (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Schedule Of Available For Sale Securities [Line Items]
Under 1 Year	$ 15,187,672
Fair Value (Net Carrying Amount)	15,187,672	$ 6,298,075
Corporate Debt Securities
Schedule Of Available For Sale Securities [Line Items]
Under 1 Year	15,187,672
Fair Value (Net Carrying Amount)	$ 15,187,672	$ 6,298,075

Property and Equipment - Summar

Property and Equipment - Summary of Property and Equipment (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Property Plant And Equipment [Abstract]
Furniture & fixtures	$ 1,086,341	$ 1,082,717
Leasehold improvements	1,931,762	1,943,534
Equipment used in manufacturing	2,673,452	2,166,743
Equipment used in research & development	2,506,644	2,506,644
Equipment used in the field	182,762	208,005
Software	488,098	420,301
Property and equipment	8,869,059	8,327,944
Less: accumulated depreciation and amortization	(7,649,869)	(7,100,542)
Property and equipment, net	$ 1,219,190	$ 1,227,402

Property and Equipment - Additi

Property and Equipment - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Property Plant And Equipment [Abstract]
Depreciation and leasehold improvement amortization expense	$ 200,000	$ 300,000	$ 568,380	$ 1,039,989

Accrued Liabilities - Summary o

Accrued Liabilities - Summary of Accrued Liabilities (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Payables And Accruals [Abstract]
Accrued employee bonuses	$ 775,219	$ 436,799
Payroll and employee benefit accruals	414,177	694,058
Accrued product warranty	92,696	92,696
Other accrued liabilities	326,909	236,325
Total accrued liabilities	$ 1,609,001	$ 1,459,878

Debt Obligations - Schedule of

Debt Obligations - Schedule of Current Portion of Long Term Debt, Net (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Current portion of long-term debt, net	$ 4,167,107	$ 3,022,139
SVB Term Loan
Debt Instrument [Line Items]
SVB Term Loan	3,750,000	2,000,000
PPP Loan
Debt Instrument [Line Items]
PPP Loan		857,040
2021 Insurance Note
Debt Instrument [Line Items]
Insurance note	$ 417,107
2020 Insurance Note
Debt Instrument [Line Items]
Insurance note		$ 165,099

Debt Obligations - Schedule o_2

Debt Obligations - Schedule of Long Term Debt, Net of Current Portion and Discount and Debt Issuance Costs (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Long term debt non current	$ 6,309,416	$ 8,568,308
SVB Term Loan
Debt Instrument [Line Items]
Loan, net of discount and debt issuance costs	$ 6,309,416	7,708,348
PPP Loan
Debt Instrument [Line Items]
PPP Loan		$ 859,960

Debt Obligations - Additional I

Debt Obligations - Additional Information (Details) - USD ($)	May 05, 2021	Jun. 25, 2020	Jun. 24, 2020	Apr. 27, 2020	Apr. 21, 2020	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Debt Instrument [Line Items]
Loss on extinguishment of MidCap Credit Facility and QNAH Convertible Note									$ (522,394)
Debt instrument, covenant unrestricted cash						$ 12,500,000		$ 12,500,000
Proceeds from Paycheck Protection Program Loan									1,717,000
Gain on forgiveness of PPP Loan								$ 1,735,792
Insurance Note
Debt Instrument [Line Items]
Debt instrument, interest rate	3.57%			3.61%
Debt instrument, maturity date	Jun. 30, 2021			Feb. 28, 2021
Down payment on insurance note	$ 400,000			$ 200,000
Premium payable on insurance note	$ 700,000			$ 700,000
Loan term	9 months			9 months
QIAGEN North American Holdings, Inc. | Convertible Promissory Note
Debt Instrument [Line Items]
Repayments of aggregate amount		$ 3,200,000
MidCap Credit Facility
Debt Instrument [Line Items]
Repayment of outstanding principal and interest		$ 7,500,000
MidCap Credit Facility | QIAGEN North American Holdings, Inc.
Debt Instrument [Line Items]
Loss on extinguishment of MidCap Credit Facility and QNAH Convertible Note									500,000
SVB Term Loan
Debt Instrument [Line Items]
Debt instrument, principal amount			$ 10,000,000
Debt instrument, interest rate			5.75%
Extend the interest-only payments			6 months
Debt instrument, maturity date			Dec. 1, 2023
Warrant to purchase common stock, shares			42,894
Warrant purchase price			$ 11.6565			$ 11.6565		$ 11.6565
Warrant expiration date			Jun. 24, 2030
Fair value of warrants			$ 400,000
Debt instrument, amortization expense						$ 100,000	$ 100,000	$ 400,000	$ 100,000
Debt discount, fees and debt issuance costs						740,584		740,584		$ 1,100,000
SVB Term Loan | Prime Rate | Minimum
Debt Instrument [Line Items]
Debt instrument, interest at floating rate			2.50%
Paycheck Protection Program Loan
Debt Instrument [Line Items]
Debt instrument, interest rate					1.00%
Paycheck Protection Program Loan | SBA
Debt Instrument [Line Items]
Accrued liability with risk of adverse review						0		0
Paycheck Protection Program Loan | Other Income (Expense)
Debt Instrument [Line Items]
Gain on forgiveness of PPP Loan						$ 0		$ 1,700,000
Paycheck Protection Program Loan | Silicon Valley Bank
Debt Instrument [Line Items]
Proceeds from Paycheck Protection Program Loan					$ 1,700,000

Debt Obligations - Schedule o_3

Debt Obligations - Schedule of Remaining Principal Repayments due Under SVB Term Loan (Details) - SVB Term Loan - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
2022	$ 5,000,000
2023	5,000,000
Total SVB Term Loan payments	10,000,000
Less discount and deferred financing costs	(740,584)	$ (1,100,000)
Plus final fee premium	800,000
Total SVB Term Loan, net	$ 10,059,416

Revenue from Contracts with C_3

Revenue from Contracts with Customers - Product and Product-Related Service Revenue from Sale of Instruments and Consumables (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Disaggregation Of Revenue [Line Items]
Product and product-related services revenue	$ 2,520,410	$ 1,777,098	$ 6,029,760	$ 5,965,866
Product and Product-related Services
Disaggregation Of Revenue [Line Items]
Product and product-related services revenue	2,520,410	1,701,068	6,029,760	5,417,731
HTG EdgeSeq | Instruments
Disaggregation Of Revenue [Line Items]
Product and product-related services revenue	407,130	71,742	1,028,348	563,396
HTG EdgeSeq | Consumables
Disaggregation Of Revenue [Line Items]
Product and product-related services revenue	793,542	764,605	2,265,894	2,091,848
HTG EdgeSeq | Product revenue
Disaggregation Of Revenue [Line Items]
Product and product-related services revenue	1,200,672	836,347	3,294,242	2,655,244
HTG EdgeSeq | Custom RUO assay design
Disaggregation Of Revenue [Line Items]
Product and product-related services revenue		238,502	48,350	1,210,968
HTG EdgeSeq | RUO Sample processing
Disaggregation Of Revenue [Line Items]
Product and product-related services revenue	1,319,738	626,219	2,687,168	1,551,519
HTG EdgeSeq | Product-related services revenue
Disaggregation Of Revenue [Line Items]
Product and product-related services revenue	1,319,738	864,721	2,735,518	2,762,487
HTG EdgeSeq | Product and Product-related Services
Disaggregation Of Revenue [Line Items]
Product and product-related services revenue	$ 2,520,410	$ 1,701,068	$ 6,029,760	$ 5,417,731

Revenue from Contracts with C_4

Revenue from Contracts with Customers - Additional Information (Details) - USD ($)	9 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Disaggregation Of Revenue [Line Items]
Agreements for product and product-related services revenue, description	the Company’s agreements for product and product-related services revenue have an expected duration of one year or less
Contract liabilities – current	$ 213,462	$ 185,083
Minimum
Disaggregation Of Revenue [Line Items]
Customer payment term	30 days
Maximum
Disaggregation Of Revenue [Line Items]
Customer payment term	90 days
Maximum | QIAGEN Manchester Limited
Disaggregation Of Revenue [Line Items]
Term of agreement	1 year

Revenue from Contracts with C_5

Revenue from Contracts with Customers - Additional Information1 (Details)	Sep. 30, 2021
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2021-10-01
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Revenue, remaining performance obligation, expected timing of satisfaction, period	1 year

Revenue from Contracts with C_6

Revenue from Contracts with Customers - Schedule of Collaborative Development Services (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Disaggregation Of Revenue [Line Items]
Service revenue	$ 2,520,410	$ 1,777,098	$ 6,029,760	$ 5,965,866
Collaborative Development Services
Disaggregation Of Revenue [Line Items]
Service revenue		$ 76,030		$ 548,135

Revenue from Contracts with C_7

Revenue from Contracts with Customers - Schedule of Changes in Contract Liability (Details) - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Disaggregation Of Revenue [Line Items]
Beginning Balance	$ 197,464	$ 599,454
Deferral of revenue	786,999	871,754
Recognition of deferred revenue	(733,939)	(946,452)
Ending Balance	250,524	524,756
Product Revenue
Disaggregation Of Revenue [Line Items]
Beginning Balance	103,580	95,148
Deferral of revenue	261,100	335,265
Recognition of deferred revenue	(198,438)	(325,181)
Ending Balance	166,242	105,232
Custom RUO Assay Design
Disaggregation Of Revenue [Line Items]
Beginning Balance		66,216
Deferral of revenue		459,385
Recognition of deferred revenue		(525,601)
Sample Processing
Disaggregation Of Revenue [Line Items]
Beginning Balance	93,884	438,090
Deferral of revenue	525,899	77,104
Recognition of deferred revenue	(535,501)	(95,670)
Ending Balance	$ 84,282	$ 419,524

Other Agreements - Additional I

Other Agreements - Additional Information (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Dec. 31, 2020USD ($)
Other Agreements [Line Items]
Accretion expense			$ (9,206)	$ (9,771)
Measurement Input, Default Rate
Other Agreements [Line Items]
Discount rate used to calculate asset purchase obligation	2.5		2.5
NuvoGen Asset Purchase Agreement
Other Agreements [Line Items]
Percentage on annual revenues for cash consideration to be paid			6.00%
Asset purchase agreement yearly fixed fees paid	$ 400,000		$ 400,000
Asset purchase agreement fixed quarterly payments	100,000		100,000
Additional revenue based payments payable	51,225		51,225		$ 54,777
NuvoGen
Other Agreements [Line Items]
Unamortized interest accretion	(70,170)		(70,170)		$ (79,376)
Accretion expense	$ (3,057)	$ (3,115)	$ (9,206)	$ (9,771)

Other Agreements - Schedule of

Other Agreements - Schedule of Remaining Minimum Principal Payments Due (Details) - NuvoGen Asset Purchase Agreement	Sep. 30, 2021USD ($)
Purchase Obligation Fiscal Year Maturity [Line Items]
2021	$ 151,225
2022	479,432
2023	400,000
2024	400,000
2025	400,000
2026 and beyond	2,702,661
Total NuvoGen obligation payments	4,533,318
Plus interest accretion	70,170
Total NuvoGen obligation, net	$ 4,603,488

Leases - Additional Information

Leases - Additional Information (Details) - USD ($)	9 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Lessee Lease Description [Line Items]
Operating lease, description	The Company’s active leases as of September 30, 2021 are for office and manufacturing space in Tucson, Arizona, which expire in 2025.
Lease expiration year	2025
Operating lease right-of-use assets	$ 1,444,348	$ 1,009,097
Financing lease liabilities, net of discount	52,635
Financing lease liabilities, current	$ 17,558
Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]	Other current liabilities
Financing lease liabilities, non current	$ 35,077
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]	Other non-current liabilities
Financing leases, right-of-use assets	$ 48,269
Tucson, Arizona
Lessee Lease Description [Line Items]
Extended lease term	The Company amended its Tucson facility leases in December 2020 to extend the terms of the leases for one year, through January 31, 2022 and again in September 2021 to extend the terms of the leases for three years, through January 31, 2025. The lease extensions were treated as lease modifications for accounting purposes, and allow for an additional extension of two years on the same terms and conditions
San Carlos, California | Research and Development Expense
Lessee Lease Description [Line Items]
Operating lease right-of-use assets	$ 200,000

Leases - Summary of Components

Leases - Summary of Components of Lease Cost for Operating Leases (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Leases [Abstract]
Operating lease cost	$ 107,969	$ 182,287	$ 383,672	$ 570,163
Variable lease cost	26,636	36,554	73,120	89,716
Operating lease expense	$ 134,605	$ 218,841	$ 456,792	$ 659,879

Leases - Summary of Other Infor

Leases - Summary of Other Information Related to Operating Leases (Details) - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Leases [Abstract]
Cash paid for amounts included in measurement of operating lease liabilities	$ 403,012	$ 665,095
Establishment of operating lease liabilities arising from obtaining right-of-use assets	$ 1,302,457	$ 21,078
Weighted-average remaining lease term – operating leases	3 years 3 months 18 days	1 year 10 months 24 days
Weighted-average discount rate – operating leases	5.80%	9.60%

Leases - Summary of Remaining M

Leases - Summary of Remaining Maturities of Operating Leases, Excluding Short-term Leases (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Leases [Abstract]
2021	$ 111,441
2022	481,549
2023	484,719
2024	484,631
2025	40,382
Total	1,602,722
Less present value discount	(148,425)
Total operating lease liabilities	1,454,297
Less operating lease liabilities - current	(398,313)	$ (685,220)
Operating lease liabilities - non-current	$ 1,055,984	$ 368,682

Leases - Summary of Component_2

Leases - Summary of Components of Lease Cost for Financing Leases (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Leases [Abstract]
Amortization of right-of-use assets	$ 5,444	$ 10,035	$ 18,501	$ 34,033
Interest on lease liability	1,369	2,092	4,544	7,074
Total financing lease cost	$ 6,813	$ 12,127	$ 23,045	$ 41,107

Leases - Summary of Other Inf_2

Leases - Summary of Other Information Related to Financing Leases (Details)	Sep. 30, 2021	Sep. 30, 2020
Leases [Abstract]
Weighted-average remaining lease term – financing leases	3 years	3 years 6 months
Weighted-average discount rate – financing leases	9.77%	9.77%

Leases - Summary of Remaining_2

Leases - Summary of Remaining Maturities of Financing Leases (Details)	Sep. 30, 2021USD ($)
Leases [Abstract]
2021	$ 5,772
2022	20,715
2023	18,396
2024	16,080
Total	60,963
Less present value discount	(8,328)
Financing lease liabilities, net	$ 52,635

Net Loss per Share - Common Sto

Net Loss per Share - Common Stock Equivalents Excluded from Computation of Diluted Net Loss per Share (Details) - shares	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Options to purchase common stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted net loss per share	494,250	499,033
Warrants | Common Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted net loss per share	58,688	58,688
Unvested Restricted Stock Units
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted net loss per share	6,301	13,603
Series A Preferred
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted net loss per share	158,545

Warrants - Additional Informati

Warrants - Additional Information (Details) - USD ($)	1 Months Ended	3 Months Ended	9 Months Ended
	Mar. 31, 2020	Jun. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Jun. 30, 2021	Jun. 24, 2020	Sep. 30, 2019
Class Of Warrant Or Right [Line Items]
Proceeds from exercise of pre-funded warrants				$ 31,768
Common Stock
Class Of Warrant Or Right [Line Items]
Number of shares issued upon the conversion		183,333	144,881
SVB Term Loan
Class Of Warrant Or Right [Line Items]
Number of securities called by warrants						42,894
Exercise price of warrants			$ 11.6565			$ 11.6565
Warrant to purchase common stock			42,894
Warrant expire date			Jun. 24, 2030
Minimum | SVB Term Loan
Class Of Warrant Or Right [Line Items]
Warrant to purchase common stock			42,894
Private Placement | Pre-funded Warrants
Class Of Warrant Or Right [Line Items]
Number of securities called by warrants	211,784
Private Placement | Institutional Accredited Investors
Class Of Warrant Or Right [Line Items]
Exercise price of warrants							$ 9.75
Private Placement | Institutional Accredited Investors | Pre-funded Warrants
Class Of Warrant Or Right [Line Items]
Number of securities called by warrants							360,779
Exercise price of warrants							$ 9.60
Exercise price of warrants, exercisable subject to beneficial ownership limitations							$ 0.15
Proceeds from exercise of pre-funded warrants	$ 31,768
Warrants exercised	211,784				148,995

Warrants -Summary of Outstandin

Warrants -Summary of Outstanding Warrants (Details) - $ / shares	9 Months Ended
	Sep. 30, 2021	Jun. 24, 2020
Series E Redeemable Convertible Preferred Stock
Class Of Warrant Or Right [Line Items]
Warrant Issuance Date	2014-08
Shares of Common Stock Underlying Warrants	1,914
Exercise Price/Share	$ 352.65
Expiration Date	2024
Convertible Note Warrants
Class Of Warrant Or Right [Line Items]
Warrant Issuance Date	2014-12
Shares of Common Stock Underlying Warrants	9,651
Exercise Price/Share	$ 210
Expiration Date	2022
Common Stock Warrants
Class Of Warrant Or Right [Line Items]
Warrant Issuance Date	2016-03
Shares of Common Stock Underlying Warrants	3,021
Exercise Price/Share	$ 41.40
Expiration Date	2026
Common Stock Tranche one
Class Of Warrant Or Right [Line Items]
Warrant Issuance Date	2018-03
Shares of Common Stock Underlying Warrants	1,208
Exercise Price/Share	$ 115.95
Expiration Date	2028
SVB Term Loan
Class Of Warrant Or Right [Line Items]
Warrant Issuance Date	2020-06
Shares of Common Stock Underlying Warrants	42,894
Exercise Price/Share	$ 11.6565	$ 11.6565
Expiration Date	2030

Stockholders Deficit - Addition

Stockholders Deficit - Additional Information (Details)

Nov. 20, 2020$ / sharesshares

Mar. 24, 2020USD ($)shares

Feb. 25, 2020USD ($)$ / sharesshares

Mar. 31, 2020USD ($)shares

Sep. 30, 2021USD ($)$ / sharesshares

Jun. 30, 2021USD ($)shares

Mar. 31, 2021USD ($)shares

Sep. 30, 2020USD ($)shares

Jun. 30, 2020USD ($)shares

Mar. 31, 2020USD ($)shares

Sep. 30, 2021USD ($)$ / sharesshares

Dec. 31, 2020USD ($)shares

Aug. 31, 2021shares

Jul. 31, 2021shares

Aug. 31, 2020shares

Nov. 30, 2019$ / shares

Sep. 30, 2019$ / sharesshares

Class Of Stock [Line Items]

Reverse stock split, description

On November 20, 2020, the Company completed a reverse stock split of its outstanding shares of common stock pursuant to which every fifteen (15) shares of issued and outstanding common stock were exchanged for one share of its common stock.

Stock split conversion ratio

0.067

Common stock split Price per share | $ / shares

$ 4.27

Fractional shares from reverse stock split share

0

Common stock, shares outstanding

7,513,733

7,513,733

5,199,997

Common stock, shares issued

7,513,733

7,513,733

5,199,997

2021 Inducement Plan

Class Of Stock [Line Items]

Grants

30,000

30,000

Employee Stock Option

Class Of Stock [Line Items]

Grants

70,333

Unrecognized compensation expense | $

$ 1,300,000

$ 1,300,000

Compensation expense period expected to be recognized

2 years 2 months 4 days

Restricted Stock Units R S U

Class Of Stock [Line Items]

Unrecognized compensation expense | $

$ 100,000

$ 100,000

Compensation expense period expected to be recognized

1 year 3 months 14 days

Vested and unissued RSU awards, description

Vested and unissued awards at September 30, 2021 represents RSU awards for which the vesting date was September 30, 2021, but for which issuance of the awards occurred in October 2021.

Vested and unissued RSU awards vesting date

Sep. 30, 2021

Vested and unissued RSU awards issuance date

Oct. 31, 2021

2020 Equity Incentive Plan

Class Of Stock [Line Items]

Shares reserved for issuance

744,685

Number of shares available for issuance

538,959

538,959

2014 Equity Incentive Plan

Class Of Stock [Line Items]

Shares reserved for issuance

68,552

Number of shares available for issuance

0

Amended and Restated 2014 Employee Stock Purchase Plan

Class Of Stock [Line Items]

Shares reserved for issuance

500,000

2014 Employee Stock Purchase Plan

Class Of Stock [Line Items]

Shares reserved for issuance

24,285

2021 Inducement Plan

Class Of Stock [Line Items]

Shares reserved for issuance

300,000

Number of shares available for issuance

270,000

270,000

Cantor Sales Agreement

Class Of Stock [Line Items]

Common stock price per share | $ / shares

$ 0.001

Exchange Agreement

Class Of Stock [Line Items]

Common stock, shares outstanding

274,000

Conversion of convertible preferred stock into common stock

6.67

Exchange Agreement | Series A Convertible Preferred Stock

Class Of Stock [Line Items]

Issuance of common stock, shares

10,170

Preferred stock, shares issued

41,100

Preferred stock, par value | $ / shares

$ 0.001

Issuance of common stock | $

$ 600,000

Stock issued, price per share | $ / shares

$ 59

Preferred stock, shares converted

27,500

Preferred stock, shares outstanding

23,770

23,770

Exchange Agreement | Common Stock

Class Of Stock [Line Items]

Number of shares issued upon the conversion

183,333

LP Purchase Agreement

Class Of Stock [Line Items]

Issuance of common stock | $

$ 599,979

Common Stock

Class Of Stock [Line Items]

Number of shares issued upon the conversion

183,333

144,881

Common Stock | LP Purchase Agreement

Class Of Stock [Line Items]

Issuance of common stock, shares

101,218

41,026

Issuance of common stock | $

$ 101

$ 41

Lincoln Park | LP Purchase Agreement

Class Of Stock [Line Items]

Gross proceeds from issuance of common stock | $

$ 600,000

Common stock value right to sell, maximum | $

$ 20,000,000

Agreement term

36 months

Common stock, shares issued

41,026

101,218

101,218

Common stock weighted average price per share | $ / shares

$ 5.93

$ 5.93

Lincoln Park | LP Purchase Agreement | Additional Paid-In-Capital

Class Of Stock [Line Items]

Commitment consideration and related transaction costs | $

$ 100,000

Private Placement | Pre-funded Warrants

Class Of Stock [Line Items]

Number of securities called by warrants

211,784

211,784

Net proceeds from sale of warrants | $

$ 31,768

Private Placement | Institutional Accredited Investors

Class Of Stock [Line Items]

Exercise Price/Share | $ / shares

$ 9.75

Private Placement | Institutional Accredited Investors | Pre-funded Warrants

Class Of Stock [Line Items]

Number of securities called by warrants

360,779

Exercise Price/Share | $ / shares

$ 9.60

Exercise price of warrants, exercisable subject to beneficial ownership limitations | $ / shares

$ 0.15

Warrants exercised

211,784

148,995

211,784

ATM Offering

Class Of Stock [Line Items]

Gross proceeds from issuance of common stock | $

$ 11,000,000

Payment of sales commissions | $

300,000

Net proceeds from issuance of common stock from the ATM Offering | $

$ 10,700,000

Issuance of common stock | $

$ 3,810,621

$ 6,855,198

$ 2,557,012

$ 1,395,058

$ 2,435,912

ATM Offering | Common Stock

Class Of Stock [Line Items]

Issuance of common stock, shares

992,834

1,058,045

263,482

138,981

293,271

2,050,879

Issuance of common stock | $

$ 993

$ 1,058

$ 263

$ 139

$ 293

Stockholders Deficit - Summary

Stockholders Deficit - Summary of Stock-Based Compensation Recorded in Condensed Consolidated Statements of Operations (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation	$ 338,893	$ 392,163	$ 1,042,318	$ 1,179,714
Selling, General and Administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation	293,916	383,679	934,446	1,079,754
Research and Development
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation	35,566	2,044	83,108	85,462
Cost of Product and Product-related Services Revenue
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation	$ 9,411	$ 6,440	$ 24,764	$ 14,498

Stockholders Deficit - Summar_2

Stockholders Deficit - Summary of Stock Option Plans Activity (Details) - Employee Stock Option	9 Months Ended	12 Months Ended
	Sep. 30, 2021USD ($)$ / sharesshares	Dec. 31, 2020USD ($)$ / sharesshares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares, Beginning Balance | shares	487,227
Number of Shares, Granted | shares	70,333
Number of Shares, Exercised | shares	(75)
Number of Shares, Forfeited | shares	(45,006)
Number of Shares, Expired/Cancelled | shares	(18,229)
Number of Shares, Ending Balance | shares	494,250	487,227
Number of Shares, Exercisable | shares	283,107
Weighted-Average Exercise Price Per Share, Beginning Balance | $ / shares	$ 16.78
Weighted-Average Exercise Price Per Share, Granted | $ / shares	5.74
Weighted-Average Exercise Price Per Share, Exercised | $ / shares	4.35
Weighted-Average Exercise Price Per Share, Forfeited | $ / shares	12.76
Weighted-Average Exercise Price Per Share, Expired/Cancelled | $ / shares	25.64
Weighted-Average Exercise Price Per Share, Ending Balance | $ / shares	15.25	$ 16.78
Weighted-Average Exercise Price Per Share, Exercisable | $ / shares	$ 20.65
Weighted-Average Remaining Contractual Life, Outstanding	8 years 2 months 12 days	8 years 7 months 6 days
Weighted-Average Remaining Contractual Life, Exercisable	7 years 7 months 6 days
Aggregate Intrinsic Value, Balance | $	$ 19,222	$ 1,536
Aggregate Intrinsic Value, Exercised | $	107
Aggregate Intrinsic Value, Exercisable | $	$ 5,882

Stockholders Deficit - Summar_3

Stockholders Deficit - Summary of Restricted Stock Unit ('RSU') Award Activity (Details) - Restricted Stock Units R S U	9 Months Ended
	Sep. 30, 2021$ / sharesshares
Restricted Stock Units (RSU)
Beginning Balance | shares	12,214
Released | shares	(3,540)
Forfeited | shares	(2,373)
Ending Balance | shares	6,301
Vested and unissued at September 30, 2021 | shares	989
Weighted Average Grant Date Fair Value Per Share
Beginning Balance | $ / shares	$ 28.61
Released | $ / shares	29.96
Forfeited | $ / shares	51
Ending Balance | $ / shares	19.40
Vested and unissued at September 30, 2021 | $ / shares	$ 26.14

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Product Warranty Liability [Line Items]
Accrued product warranty	$ 92,696	$ 92,696
Accrued Liabilities
Product Warranty Liability [Line Items]
Accrued product warranty	93,000
Other Non-Current Liabilities
Product Warranty Liability [Line Items]
Product warrant liabilities	$ 27,000

Commitments and Contingencies_2

Commitments and Contingencies - Summary Of Product Warranty Liability (Details) - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Commitments And Contingencies Disclosure [Abstract]
Beginning balance	$ 92,696	$ 94,482
Cost of warranty claims	(141,648)	(19,310)
Increase in warranty reserve	169,337	12,423
Ending balance	$ 120,385	$ 87,595